US.PFE · Pfizer

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 1.961038961038961,
        "turnoverUsdM": 707.68478088,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1.2
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.PFE",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 26.6328,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2.5,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.3,
      "stop_loss_percent": 3.9,
      "take_profit_price": 29.106,
      "target_multiplier": 1.6,
      "technical_strength": 1.45,
      "take_profit_percent": 5
    },
    "positionPoints": 1.8,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.274834437086093,
    "stopLossPercent": 3.922077922077922,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 54.7,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 48.7,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 6
  },
  "market": {
    "ma20": 28.003,
    "ma50": 26.2684,
    "close": 27.72,
    "prevClose": 27.65,
    "avgVolume20": 32796658,
    "volumeRatio": 0.78,
    "changePercent": 0.25
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 6,
    "details": {
      "ret_5d": -0.03783408538701838,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 6,
      "vcp_bonus": 2,
      "vol_ratio": 0.7669365740646168,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 0.8422927588545609,
      "volat_points": 0,
      "day_range_pct": 0.015512265512265503,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 4,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 54.7,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 50,
        "contribution": 2.5
      },
      {
        "raw": 9.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 46,
        "contribution": 9.2
      },
      {
        "raw": 8.4,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 56,
        "contribution": 8.4
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 76,
        "contribution": 7.6
      },
      {
        "raw": 17,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 56.67,
        "contribution": 17
      },
      {
        "raw": 2,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 20,
        "contribution": 2
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 48.7,
    "details": [
      "基本面分析總分: 2.5/5分",
      "資金流分析總分: 9.2/20分",
      "市場環境分析總分: 8.4/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.6/10分",
      "技術信號分析總分: 17/30分",
      "情緒分析: 2/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.5,
      "資金流": 9.2,
      "市場環境": 8.4,
      "情緒分析": 2,
      "技術信號": 17,
      "風險管理": 7.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 707.68478088,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 1.6,
          "obvPoints": 2.4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.PFE",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 2.8,
            "details": {
              "qqq": {
                "ma20": 715.6679992,
                "ma50": 710.4063990999997,
                "name": "QQQ",
                "close": 714.88,
                "points": 1.4
              },
              "spy": {
                "ma20": 766.87899445,
                "ma50": 758.61640102,
                "name": "SPY",
                "close": 764.28998,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 1.961038961038961,
          "atrPoints": 4,
          "cciPoints": 1.6,
          "vixPoints": 0,
          "marketTrendPoints": 2.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 1,
              "positiveHits": 1,
              "sentimentScoreRaw": 0
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142028628,
                "url": "https://finnhub.io/api/news?id=1197e6dcb84032bc3178511ebc59fde338fc46553b3e766a32b3e59929344ec1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I’ll tell you… I think it’s always good to look at Lilly as a stock […]",
                "category": "company",
                "datetime": 1788981160,
                "headline": "Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks"
              },
              {
                "id": 141406924,
                "url": "https://finnhub.io/api/news?id=b8801f010fae69f2a2f7c854843df9bcdb74501e16bac04a27d4a1d4c8c88781",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer stock has quietly put up a 25.6% gain over the past year, yet broad valuation checks still do not flag it as either clearly cheap or clearly expensive. With mixed signals on value and fresh product news in the background, investors are weighing how much of the recent optimism is already reflected in the share price. The 25.6% 1 year return suggests sentiment toward Pfizer has improved meaningfully, which raises the bar for further upside driven purely by valuation. Approval of Pfizer...",
                "category": "company",
                "datetime": 1788484058,
                "headline": "Pfizer (PFE) Stock Looks Fully Valued As Earnings Run Ahead Of Value"
              },
              {
                "id": 141406925,
                "url": "https://finnhub.io/api/news?id=a34b1dfd8e66c37400dc51e62e40dcbc2c33200ec487fd34ab3e4761ec503ab6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) has drawn fresh attention after the FDA approved its 2026 to 2027 COMIRNATY XFG COVID-19 vaccine formula for high risk age groups, adding a new chapter to the company’s vaccine story. Pfizer’s recent FDA approval adds to a string of positive updates that helped lift the share price to around a two year high, with a 30 day share price return of 13.38% and year to date share price return of 14.42%. The 1 year total shareholder return of 25.63% contrasts with a weaker 5 year total...",
                "category": "company",
                "datetime": 1788481325,
                "headline": "Pfizer (PFE) After FDA Vaccine Approval Faces A Fair Value Reality Check"
              },
              {
                "id": 141400360,
                "url": "https://finnhub.io/api/news?id=1d4d3880694c9b85844e53ef2e9fdcc233f5c7a2de000b7984566a92a2fc0394",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788449421,
                "headline": "Pfizer (PFE) Up 12.4% Since Last Earnings Report: Can It Continue?"
              },
              {
                "id": 141395432,
                "url": "https://finnhub.io/api/news?id=03c9adcf8e3d1f13805545b15f25bf91f5c378ae6fd56b650d6edaa8e3b77049",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer, GitLab, and Conoco Phillips shares surged to 52-week highs on Wednesday amid a series of positive company catalysts and optimistic Wall Street coverage.",
                "category": "company",
                "datetime": 1788411118,
                "headline": "Why Did PFE, GTLB, COP Stocks Jump To 52-Week Highs Today?"
              },
              {
                "id": 141361962,
                "url": "https://finnhub.io/api/news?id=1eb020282d63561578c91813d292244c3487cb4cbce6213ce0b6ea900ac49ef7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (NYSE:PFE) has reached a confidential settlement covering federal lawsuits over its Depo-Provera contraceptive and alleged intracranial meningioma risk. The agreement reportedly addresses more than 6,000 cases, with financial terms not disclosed and no admission of liability by Pfizer. The resolution closes a multi year legal overhang tied to Depo-Provera and brings clarity to a significant product liability dispute. This kind of large scale legal settlement can shift how investors...",
                "category": "company",
                "datetime": 1788211345,
                "headline": "Pfizer (PFE) Reaches Confidential Settlement In Depo Provera Litigation"
              },
              {
                "id": 141279211,
                "url": "https://finnhub.io/api/news?id=ca6f2c7d9ec1e90d62aaba8967fad5a833bf772134237c2edb5e2eff87bc99f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer has been treading water for the past six months, recording a small return of 2.6% while holding steady at $27.76. The stock also fell short of the S&P 500’s 12.7% gain during that period.",
                "category": "company",
                "datetime": 1787340947,
                "headline": "2 Reasons to Watch PFE and 1 to Stay Cautious"
              },
              {
                "id": 141206622,
                "url": "https://finnhub.io/api/news?id=834e68a730234edefb17d792b46fff00c1c6f2944ccc0a22b3f604a8b4eb6da1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "In early August 2026, Pfizer Inc. reported second-quarter results showing revenue of US$15,034 million and a net loss of US$248 million, alongside US$4.30 billion in non-cash intangible asset impairments and a modest increase in full-year 2026 revenue guidance to US$60.50–US$62.50 billion. A key offsetting highlight was the positive Phase 3 data for Pfizer’s autoimmune drug LITFULO in nonsegmental vitiligo, underlining the growing importance of its non-COVID portfolio and broader immunology...",
                "category": "company",
                "datetime": 1786633961,
                "headline": "How Pfizer’s Higher 2026 Guidance And LITFULO Trial Results At Pfizer (PFE) Have Changed Its Investment Story"
              }
            ],
            "raw_source": [
              {
                "id": 142089433,
                "url": "https://finnhub.io/api/news?id=4ae9498ecd56e299779ddffb0f6ac4ad216aa14954b49be19d26f04673465af6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AbbVie (ABBV) grew revenue 10.4% over the past twelve months and turned 33.9% of it into operating profit, second only to Eli Lilly among its peers on both counts. Its stock returned 24.9% over the same twelve months, fifth of the six. What the business delivered and what the market paid for it have come apart.",
                "category": "company",
                "datetime": 1789153872,
                "headline": "Is AbbVie Stock Actually Overpriced?"
              },
              {
                "id": 142088308,
                "url": "https://finnhub.io/api/news?id=925c03514d31e7f4c0ae7b4cb8b9171c087f47b6f1408bb0b633703c56351c2d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Holding high-yield dividend stocks like BDCs and REITs in the wrong account silently erases hundreds of dollars every year, and most investors never see it happening until they run the actual numbers.",
                "category": "company",
                "datetime": 1789143127,
                "headline": "The Dividend Stocks That Generate $6,400 Tax-Free Inside a Roth (And What They Cost You in a Taxable Account)"
              },
              {
                "id": 142082893,
                "url": "https://finnhub.io/api/news?id=880933dfbd09e43b4fbc32f79aae5af35c9792716d2b6688e9303c504192cb40",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Treasury yields are making income investors work harder than they have in years, and most dividend stocks no longer clear the bar. Six still do, but yield alone is the easy part of the analysis.",
                "category": "company",
                "datetime": 1789130864,
                "headline": "The 10-Year Treasury Pays Nearly 5% These 6 Dividend Stocks Still Pay More"
              },
              {
                "id": 142079237,
                "url": "https://finnhub.io/api/news?id=7b550bc54d2ebe434f4dd008993045367822012ab015344290241d1ca76cdbba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "U.S. stock market funds defied the normal late-summer doldrums in August, shrugging off rising bond yields and finishing the month higher.",
                "category": "company",
                "datetime": 1789126543,
                "headline": "U.S. Stock Funds Rebound In August And Snub Bond Market Warning"
              },
              {
                "id": 142086503,
                "url": "https://finnhub.io/api/news?id=e628c29605c5f0847b5aef56a86ce8a16d5789c9f8ef65443d363904182bc5ce",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/11/Number-Of-Cigarettes-Isolated-Tobacco-Da.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "President Trump's Surgeon General nominee Dr. Nicole Saphier disclosed investments in Philip Morris and other companies, agreeing to divest if confirmed.",
                "category": "company",
                "datetime": 1789097046,
                "headline": "Trump's Surgeon General Pick Has Tobacco, Cola Stocks In Portfolio Even as Robert Kennedy Jr. Wages War On Sugary Drinks, Processed Food"
              },
              {
                "id": 142064830,
                "url": "https://finnhub.io/api/news?id=bd17cb9cda6dc074bed2fee359f25f1a2eb12938c3218f7db9d4c08f6eaf1efc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.",
                "category": "company",
                "datetime": 1789064040,
                "headline": "Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow."
              },
              {
                "id": 142064831,
                "url": "https://finnhub.io/api/news?id=5c23da2da14b7dde9d21b00a5bd3bf7b5666887e23f4ec0fb981bf196bd4c316",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Novavax (NASDAQ:NVAX) executives outlined the company’s transition from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, with near-term attention on Sanofi’s commercial rollout of NUVAXOVID, combination vaccine development and early",
                "category": "company",
                "datetime": 1789063342,
                "headline": "Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot"
              },
              {
                "id": 142064746,
                "url": "https://finnhub.io/api/news?id=1abe8e7dab24ae7989315403c7be9a89f24836f0d543d8d14ac5a49793d3b96e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "A healthcare titan is in a full sprint, but a recent stumble has investors asking if the best part of the race is already over.",
                "category": "company",
                "datetime": 1789063054,
                "headline": "JNJ Stock: Is the Rally Running Out of Steam?"
              },
              {
                "id": 142063291,
                "url": "https://finnhub.io/api/news?id=45a4c767641875677341490c5c57df95988778e7db0af9183d8a84bc58b8398b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "If you hold Pfizer (PFE) or Zoetis (ZTS), you hold the same idea: a branded medicine becomes a standard of care and keeps earning for years, in people or in animals. That is where it stops. Pfizer is buying replacements for older drugs losing exclusivity. Zoetis is cutting its effective price to keep the franchises it has. Same bet, two opposite defenses.",
                "category": "company",
                "datetime": 1789059954,
                "headline": "Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?"
              },
              {
                "id": 142063372,
                "url": "https://finnhub.io/api/news?id=077c6fb6bfc1689705d3cdb8bb5fe9c60920ed9d482c6f0efae052396a7b993b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss a transformative agreement with Pfizer that significantly strengthens the company’s position in precision oncology and provides key resources to advance its lead cancer program. Under the development and licensing agreement, Medicus has secured rights to a CD228-targeted antibody-drug conjugate (ADC) program, while Pfizer is contributing approximately $2 million in development funding, along with inventory and infrastructure support. Bokhari described the transaction as a major milestone that effectively provides the company with the resources needed to continue development from where Pfizer concluded its Phase 1 dose-escalation work. The CD228-targeted ADC is being developed for the treatment of solid tumors, including refractory melanoma, and now represents the centerpiece of Medicus’ evolving oncology strategy. Bokhari said the agreement allows the company to move forward with a capital-efficient approach while leveraging the extensive scientific and clinical groundwork already completed by Pfizer. Beyond oncology, Medicus continues to make progress with its SkinJect program, which is focused on the treatment of basal cell carcinoma and related conditions. Bokhari noted that final clinical trial results recently published on ClinicalTrials.gov identified the 200-microgram patch as the optimal dose for future registrational studies. The company is now concentrating its efforts on advancing SkinJect in patients with Gorlin syndrome, a rare genetic condition that can lead to the development of multiple basal cell carcinomas throughout a patient’s lifetime. Medicus is preparing to move forward with the FDA-approved pivotal SkinJect 005 study while simultaneously recruiting patients for the trial. At the same time, Bokhari said the company is positioning the broader nodular basal cell carcinoma opportunity for potential out-licensing, allowing Medicus to focus internal resources on the areas where it sees the strongest risk-adjusted return. To support the commercial potential of SkinJect, Medicus commissioned an independent reimbursement analysis that suggests the treatment could potentially achieve reimbursement levels of $25,000 or more per patient. Bokhari noted that the rare disease and potential pediatric disease characteristics associated with Gorlin syndrome could provide attractive regulatory and commercial advantages. He described SkinJect as “partner-ready” and indicated that the company is actively exploring opportunities to unlock additional value through strategic partnerships. Bokhari characterized the Pfizer agreement as a paradigm shift for Medicus, transforming the company into a precision oncology-focused biotechnology business while maintaining a disciplined approach to capital allocation. He compared the strategy to a Berkshire Hathaway-style model for drug development, where resources are selectively deployed into programs with the highest potential returns. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #SkinJect #Pfizer #PrecisionOncology #Biotech #CancerResearch #ADC #Melanoma #DrugDevelopment #ClinicalTrials #SkinJect #GorlinSyndrome #Biotechnology #HealthcareInnovation #Oncology #LifeSciences",
                "category": "company",
                "datetime": 1789055908,
                "headline": "Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy"
              },
              {
                "id": 142061785,
                "url": "https://finnhub.io/api/news?id=319f28aeaea63b63ec1d3933aeb670aebb9c5465de023eaec04e187f46e57e89",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AbbVie (ABBV) has returned 23.3% over the past year, ahead of the S&P 500's (SPY) 18.5%, and the business behind that return has changed shape. Humira, the drug whose decline management once explained, took one sentence on the July 2026 earnings call. What that sentence no longer contains is the part a holder should look at.",
                "category": "company",
                "datetime": 1789052702,
                "headline": "Why Has AbbVie Gone Quiet About Humira?"
              },
              {
                "id": 142061790,
                "url": "https://finnhub.io/api/news?id=f072b00dc7b6eab88f5d8cacd9b597e339cba962aeadc83abd5997d2f4a446c6",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "HSBC  analyst Rajesh Kumar   maintains Pfizer (NYSE:PFE) with a Hold and raises the price target from $28 to $30.",
                "category": "company",
                "datetime": 1789033210,
                "headline": "HSBC Maintains Hold on Pfizer, Raises Price Target to $30"
              },
              {
                "id": 142060553,
                "url": "https://finnhub.io/api/news?id=de0863dd4de4a07e66f5147a752f06269e121c59f01f7c1765fbdac26551f7a6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2227945708/image_2227945708.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Pfizer's pipeline strength is evident, especially with berobenatide and Vyndamax, providing a bridge over the 2028 LOE trough. Read why PFE stock is a buy.",
                "category": "company",
                "datetime": 1789032062,
                "headline": "Pfizer: Firing On All Cylinders"
              },
              {
                "id": 142037821,
                "url": "https://finnhub.io/api/news?id=111db1e73b95e44821420ce4a7307dd477cbd22ec124737b00e8ef9d99e156e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Amgen (AMGN) trades at about $393 a share. On the last twelve months of adjusted earnings, that is a trailing multiple of about 23.3 times. With Prolia and XGEVA sales falling to biosimilar rivals, the multiple looks full. What the forecast underneath it asks for is a wider margin while the company funds MariTide.",
                "category": "company",
                "datetime": 1789007538,
                "headline": "Amgen's Forward Multiple Looks Cheap Until You Price The Margins It Assumes"
              },
              {
                "id": 142029776,
                "url": "https://finnhub.io/api/news?id=d0731908caf2bd1afebdf178ac483ad1e6acebd96431ddace79e6a6f8dcaac48",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Eli Lilly (LLY) stock has gained about 56% over the past year, moving from $722.65 to $1,123.91. Before that run the company was doing something strange. It was deliberately selling less medicine than people wanted to buy, and it kept saying so out loud.",
                "category": "company",
                "datetime": 1788986503,
                "headline": "What Eli Lilly Was Telling You While It Rationed Its Own Launches"
              },
              {
                "id": 142028628,
                "url": "https://finnhub.io/api/news?id=1197e6dcb84032bc3178511ebc59fde338fc46553b3e766a32b3e59929344ec1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I’ll tell you… I think it’s always good to look at Lilly as a stock […]",
                "category": "company",
                "datetime": 1788981160,
                "headline": "Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks"
              },
              {
                "id": 142025934,
                "url": "https://finnhub.io/api/news?id=d1481c236105abdcdbc3aea4d536f65aae4822bcacac040ffaa2180f7558e388",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) said it appointed Raju Willener as Chief Financial Officer, having previously served as Director of Corporate Development at Exentis Group AG, before becoming its CFO in 2025. Mr. Willener has more than three decades of international financial leadership experience in global capital markets and all aspects of […] The post VERAXA Biotech Designates Raju Willener as CFO appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1788968785,
                "headline": "VERAXA Biotech Designates Raju Willener as CFO"
              },
              {
                "id": 142026040,
                "url": "https://finnhub.io/api/news?id=333334eda2ba9d087fb72596cdd283ee2c92c0aaf412bd1e52ea26901167094d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Wellcome Leap (Leap), a U.S. nonprofit founded by the Wellcome Trust to accelerate breakthroughs in human health, today announced that John Young and Thomas Glanzmann have joined its Board of Directors. “Throughout my career, I have seen what becomes possible when exceptional science is matched with urgency, clear goals, and the ability to operate at scale,” said John Young. “Wellcome Leap brings those elements together in a unique way – assembling m",
                "category": "company",
                "datetime": 1788966000,
                "headline": "Wellcome Leap Appoints John Young and Thomas Glanzmann to Board of Directors"
              },
              {
                "id": 142024781,
                "url": "https://finnhub.io/api/news?id=807f866ec62b46b4828740d606fbc8a4a836999841ad8b85b5221fb8068fc8f8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Collecting $8,900 a month in retirement without selling shares sounds clean until you see what the biggest position in this seven-ticker setup actually pays when markets go quiet.",
                "category": "company",
                "datetime": 1788959092,
                "headline": "How a 74-Year-Old Collects $8,900 a Month Without Selling a Single Share"
              },
              {
                "id": 142024649,
                "url": "https://finnhub.io/api/news?id=80b02bb7269462efc01e59f3e246723b4625b7b71f85d649411bab359c07e4a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Three exceptional Oregon students have been awarded Tech Mastery Scholarships from Rentec Direct as they pursue technology degrees and prepare for careers in high-demand fields. The 2026 recipients represent the next generation of technology leaders and the latest class of students supported through Rentec Direct's decade-long investment in developing Oregon's future tech workforce.",
                "category": "company",
                "datetime": 1788958800,
                "headline": "Meet Oregon's Next Generation of Tech Talent: Rentec Direct Awards 2026 Tech Mastery Scholarships"
              },
              {
                "id": 142024724,
                "url": "https://finnhub.io/api/news?id=dd8e631b9b07bac1d3fdab7717c62d52f885956485a88d4a82f29eb55e8e7602",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "PFE's non-COVID growth, oncology pipeline and cost cuts offer a path forward as COVID sales fall and patent losses loom.",
                "category": "company",
                "datetime": 1788955860,
                "headline": "Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?"
              },
              {
                "id": 142024373,
                "url": "https://finnhub.io/api/news?id=233655d956f8982870f75e6a03c17d352c8ad2e764b88ad3e1e654b329ae90b4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1252670521/image_1252670521.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Five S&P 500 stocks—VICI, PFE, VZ, T, F—offer 'safer' high yields, with free cash flow covering dividends and dividends from $1K invested exceeding share...",
                "category": "company",
                "datetime": 1788942430,
                "headline": "Buy 5 S&P500 IDEAL 'Safer' September Dividend Dogs"
              },
              {
                "id": 141955000,
                "url": "https://finnhub.io/api/news?id=f3c1a474b396ae61450cfcbc3ba7c42a4f48ce84b8d7b868c92eed14d725c1cb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The beaten-down pharmaceutical stock was revived after it posted an estimates-beating quarter.",
                "category": "company",
                "datetime": 1788900855,
                "headline": "Why Pfizer Stock Was so Healthy in August"
              },
              {
                "id": 141952570,
                "url": "https://finnhub.io/api/news?id=5705e6aac332197632f6883717364f774adac3cf64f03b6da96a17c69f795736",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AbbVie (ABBV) trades at $256.46, roughly 96% of its 52-week high, after returning 24.1% over the past twelve months against 19.7% for the S&P 500. That price buys a business where about a third of guided 2026 revenue comes from one drug. The market reads that concentration as strength. It is worth reading it the other way too.",
                "category": "company",
                "datetime": 1788887331,
                "headline": "Is AbbVie Stock Too Reliant On Skyrizi?"
              },
              {
                "id": 141952507,
                "url": "https://finnhub.io/api/news?id=5bc48b8fcb4082ca3a778081490904fe5568769496d5f9bf7ced0e48723eb43c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior.",
                "category": "company",
                "datetime": 1788887100,
                "headline": "Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now"
              },
              {
                "id": 141950162,
                "url": "https://finnhub.io/api/news?id=70423431bc7b150e3630ade48f615f5dd07d0c36f4e85b7c28b19b44f9016e98",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Moderna stock surges 143% in a month on positive cancer therapy results, but competition and valuation raise key questions for investors.",
                "category": "company",
                "datetime": 1788878400,
                "headline": "MRNA Stock Soars 143% in a Month: Time to Buy, Hold or Sell?"
              },
              {
                "id": 141949985,
                "url": "https://finnhub.io/api/news?id=23e22eca29f124149162f38fb98cc7d4fd8a268c0cb690d6bdce0f160f07e68b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Merck (MRK) has returned about 85% over the past year and at about $150 trades roughly 4% below its 52-week high. A year ago, management spent earnings calls managing fallout from a steep drop in GARDASIL sales. That problem has left the lead. What management opens with instead is a much larger claim, and it settles years from now.",
                "category": "company",
                "datetime": 1788878194,
                "headline": "What Merck Stopped Saying About GARDASIL Should Change What You Watch"
              },
              {
                "id": 141950556,
                "url": "https://finnhub.io/api/news?id=08300e39c77d680ab5e7a4f13974480802f6ddb9b5122762586f5dbd571da750",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "NEW YORK, September 08, 2026--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 10:45 a.m. EDT.",
                "category": "company",
                "datetime": 1788876000,
                "headline": "Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference"
              },
              {
                "id": 141950561,
                "url": "https://finnhub.io/api/news?id=3b332d2f40663430ea9a09cc1fbc6678f0df666059a5b97a200a7986df8d8c79",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Medicus Pharma Ltd. (MDCX) has outlined a revised development strategy that makes CD228V, its second-generation antibody-drug conjugate targeting melanotransferrin/CD228, the company’s principal clinical programme.",
                "category": "company",
                "datetime": 1788872030,
                "headline": "Medicus Pharma Prioritises CD228V Oncology Programme in Development Strategy"
              },
              {
                "id": 141949974,
                "url": "https://finnhub.io/api/news?id=b2ec4341f3666dff5619e2b1d8bf38bc580c8ddb9dd8a17f52bb9771272207d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Lilly is expanding its neuroscience pipeline through strong growth and M&A, aiming to build a new long-term driver beyond cardiometabolic therapies.",
                "category": "company",
                "datetime": 1788870420,
                "headline": "Lilly Builds Neuroscience into a New Long-Term Growth Driver"
              },
              {
                "id": 141950419,
                "url": "https://finnhub.io/api/news?id=0541994b63d05ef6ea832adc3d6f0597ce67a6aedbb21537b86872caa33c3402",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Why choose between double-digit percentage gains on stocks and insane 5.2%-plus yields on long-term Treasurys? You can have both.",
                "category": "company",
                "datetime": 1788867398,
                "headline": "4 Stocks Whup The S&P 500 — And Yield More Than 30-Year Treasurys"
              },
              {
                "id": 141949322,
                "url": "https://finnhub.io/api/news?id=4327394c95660a20d019c67d42085de8642f275075d61e1337f760a5b7bc2062",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2285918278/image_2285918278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "NewAmsterdam Pharma (NAMS) has seen a near 40% stock pullback post-Merck’s Lipfendra approval, but retains multi-blockbuster potential with obicetrapib. Read the latest on the stock here.",
                "category": "company",
                "datetime": 1788862119,
                "headline": "NewAmsterdam Pharma: Potential Coupled With Uncertainty"
              },
              {
                "id": 141877377,
                "url": "https://finnhub.io/api/news?id=938d5badb78216656ed52d48f4df5fe8333d40c1b541b0536c85312c59a8b916",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The purchase adds an established hypertension brand to the company's cardiovascular range.",
                "category": "company",
                "datetime": 1788857510,
                "headline": "Novartis India acquires Pfizer brands for $132m"
              },
              {
                "id": 141948955,
                "url": "https://finnhub.io/api/news?id=d3d1a380b95492109fe7307d02168b156b4c4a80de9fc5a262c0b1e539182525",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2199578213/image_2199578213.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Dividend Harvesting Portfolio update: 45.8% ROI, $3,289 forward annual income, 7.83% yield. Click here to read more.",
                "category": "company",
                "datetime": 1788856238,
                "headline": "Dividend Harvesting Portfolio Week 288: $28,800 Allocated, $3,289.51 In Projected Dividends"
              },
              {
                "id": 141771129,
                "url": "https://finnhub.io/api/news?id=8d4ddd4505d0a2c0a565fc6aa50cad54667e4793873643445d02cbd7344ed953",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are building a separate case altogether for investors willing to look past the dividend.",
                "category": "company",
                "datetime": 1788800445,
                "headline": "Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now"
              },
              {
                "id": 141771130,
                "url": "https://finnhub.io/api/news?id=b9e06ae22a5e4c2a6e09314150400ac04b567e316d83e4ca72b0070fbd64d175",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The pharmaceutical stock is struggling, but its dividend can be highly valuable to income investors.",
                "category": "company",
                "datetime": 1788796201,
                "headline": "This Is What I'd Do With Pfizer Stock Right Now"
              },
              {
                "id": 141762863,
                "url": "https://finnhub.io/api/news?id=41ffd461059d01b83af5f6b005e0cd9ed487a6bbd0d0ecd81a797819bfe6cdb1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AZN's Etcamah wins accelerated FDA approval for certain advanced breast cancer patients, backed by a 56% risk reduction in progression or death.",
                "category": "company",
                "datetime": 1788784860,
                "headline": "AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah"
              },
              {
                "id": 141760935,
                "url": "https://finnhub.io/api/news?id=9f51313c5b3c77384d06c621b598127ced700b1ca8ebed5cb5ba133ec949c83a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The \"Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Till 2035\" has been added to ResearchAndMarkets.com's offering. The global vaccines market is projected to increase from approximately USD 48 billion to USD 94 billion by 2030, representing a compound annual growth rate of about 11.9% during the forecast period. Market expans",
                "category": "company",
                "datetime": 1788778920,
                "headline": "Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva"
              },
              {
                "id": 141455037,
                "url": "https://finnhub.io/api/news?id=882e78db4092ee8e4a4f8c9153c570608198427b13f54f3413147816ac706bb2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.",
                "category": "company",
                "datetime": 1788547801,
                "headline": "AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 141444058,
                "url": "https://finnhub.io/api/news?id=905919b186b2cb70f624aa1750860bd8a239d54c5d4daa0db9581cc8254fae21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbed, and its talc litigation now has a proposed ending. Both are real. The first does not explain a move that size, and the second is not finished.",
                "category": "company",
                "datetime": 1788541047,
                "headline": "Was JNJ Stock Rally Actually Its Own?"
              },
              {
                "id": 141431642,
                "url": "https://finnhub.io/api/news?id=30c88d515f9a37e92b3066e6f44c71beb646245c32bfe22b3b84e95acef516c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about keeping that payout alive through what could be the company's toughest stretch in years.",
                "category": "company",
                "datetime": 1788532931,
                "headline": "Pfizer’s Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?"
              },
              {
                "id": 141431557,
                "url": "https://finnhub.io/api/news?id=313180c035e4932f2abc58e42e6e670c0e2e69ccec43a80dfb30eb8824b93639",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Amgen's MariTide could target obesity with less frequent dosing, offering a convenience edge as competition from Lilly and Novo Nordisk intensifies.",
                "category": "company",
                "datetime": 1788530700,
                "headline": "AMGN's MariTide: Can Convenience Drive its Obesity Market Share?"
              },
              {
                "id": 141446631,
                "url": "https://finnhub.io/api/news?id=acc97bf164cbb510d5f95d4dd90bb12e4789e33a92896040efbc52ce5956ac8f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.",
                "category": "company",
                "datetime": 1788523200,
                "headline": "Trailing rivals, AbbVie scores win with dual-acting myeloma drug"
              },
              {
                "id": 141437549,
                "url": "https://finnhub.io/api/news?id=40091ef4bebb8b22182180fc8c591fba8d6a34b4d89f7e67eda76297f4868680",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.",
                "category": "company",
                "datetime": 1788512400,
                "headline": "Ionis’ rare neurology drug approved; Pfizer inks an ADC deal"
              },
              {
                "id": 141406924,
                "url": "https://finnhub.io/api/news?id=b8801f010fae69f2a2f7c854843df9bcdb74501e16bac04a27d4a1d4c8c88781",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer stock has quietly put up a 25.6% gain over the past year, yet broad valuation checks still do not flag it as either clearly cheap or clearly expensive. With mixed signals on value and fresh product news in the background, investors are weighing how much of the recent optimism is already reflected in the share price. The 25.6% 1 year return suggests sentiment toward Pfizer has improved meaningfully, which raises the bar for further upside driven purely by valuation. Approval of Pfizer...",
                "category": "company",
                "datetime": 1788484058,
                "headline": "Pfizer (PFE) Stock Looks Fully Valued As Earnings Run Ahead Of Value"
              },
              {
                "id": 141406925,
                "url": "https://finnhub.io/api/news?id=a34b1dfd8e66c37400dc51e62e40dcbc2c33200ec487fd34ab3e4761ec503ab6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) has drawn fresh attention after the FDA approved its 2026 to 2027 COMIRNATY XFG COVID-19 vaccine formula for high risk age groups, adding a new chapter to the company’s vaccine story. Pfizer’s recent FDA approval adds to a string of positive updates that helped lift the share price to around a two year high, with a 30 day share price return of 13.38% and year to date share price return of 14.42%. The 1 year total shareholder return of 25.63% contrasts with a weaker 5 year total...",
                "category": "company",
                "datetime": 1788481325,
                "headline": "Pfizer (PFE) After FDA Vaccine Approval Faces A Fair Value Reality Check"
              },
              {
                "id": 141404395,
                "url": "https://finnhub.io/api/news?id=e587a2d9ab3e87231966dc13003c0cd2b6fa39a9dd3601ea579187559479cd93",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Luis Jodar, Ph.D., Former Pfizer Chief Medical Officer for Vaccines and Infectious Diseases with Extensive Leadership Experience Across Clinical Development and Medical Affairs for Pneumococcal Conjugate Vaccines Prevnar 13 and Prevnar 20, Joins Vaxcyte as Chief Medical Officer David McAvoy, J.D., Former Teva Chief Legal Officer, Joins Vaxcyte as Chief Legal Officer Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Pivotal Trial Expected by End of October 2026",
                "category": "company",
                "datetime": 1788469500,
                "headline": "Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data"
              },
              {
                "id": 141403729,
                "url": "https://finnhub.io/api/news?id=24e76f9037e7e683a673304610500eca3240fe709c89f1e7a381a2ff30673f2c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "After a long bout with poor post-pandemic performance, the stock's starting to perk up. The question is, are other investors -- and analysts -- willing to stick their neck out any further anytime soon?",
                "category": "company",
                "datetime": 1788462300,
                "headline": "3 Things You Need to Know If You Buy Pfizer Stock Today"
              },
              {
                "id": 141401562,
                "url": "https://finnhub.io/api/news?id=1f94100c220d7a64393c01745fc80348758aa2c70eaf3e505da0a90106a9fa2b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Merck’s stock is the top performer in its group, but its profitability sits at the very bottom of the pack, forcing a hard question on investors.",
                "category": "company",
                "datetime": 1788455269,
                "headline": "Is Merck Stock Pricing In A Post-Keytruda Future Too Soon?"
              },
              {
                "id": 141401623,
                "url": "https://finnhub.io/api/news?id=571938922c53a24695a79bd4b7bcf6cadc277e382964d905e6dd29c162da8113",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Summit says its ivonescimab is keeping lung-cancer patients alive longer than Keytruda does. The stock is up.",
                "category": "company",
                "datetime": 1788454800,
                "headline": "Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug"
              },
              {
                "id": 141401563,
                "url": "https://finnhub.io/api/news?id=50bde06ec4383c3e8fc1744e10def00da142de1f05932785daae894c39691680",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "A pharma giant delivered substantial cash returns to shareholders while outperforming the broader market. Here is a breakdown of AbbVie's cash-return capacity, and the key commercial metric supporting its durability.",
                "category": "company",
                "datetime": 1788454466,
                "headline": "ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care?"
              },
              {
                "id": 141400360,
                "url": "https://finnhub.io/api/news?id=1d4d3880694c9b85844e53ef2e9fdcc233f5c7a2de000b7984566a92a2fc0394",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788449421,
                "headline": "Pfizer (PFE) Up 12.4% Since Last Earnings Report: Can It Continue?"
              },
              {
                "id": 141400340,
                "url": "https://finnhub.io/api/news?id=d605837c09a466bf298019b4b1f79af8743705ece69897637d710b520f1b2b7e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Johnson & Johnson (JNJ) has had a good year. The stock is up 56.5% over the past twelve months against 19.1% for the S&P 500, and at $271.19 sits at about 99% of its 52-week high. The business is still growing. The risk is that the current stock price discounts an acceleration well ahead of management's near-term guidance.",
                "category": "company",
                "datetime": 1788449092,
                "headline": "Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided?"
              },
              {
                "id": 141400341,
                "url": "https://finnhub.io/api/news?id=ad022e5bc8dde3e4d944411bba52005d8a98c7c6847a875884ffee4bfc31fea2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "PFE's pipeline is taking center stage as berobenatide and next-generation oncology drugs aim to drive growth from 2028 and beyond.",
                "category": "company",
                "datetime": 1788448140,
                "headline": "Pfizer's Pipeline Strategy Centers on Obesity and Oncology"
              },
              {
                "id": 141402548,
                "url": "https://finnhub.io/api/news?id=ed7927f2a9ddb90a8e36bfbd569bd70bb2262a3052ec13bc53b358d2105fa7c4",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/03/Franklin---April-21--2024-Pfizer-Site-Ma.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Medicus Pharma partners with Pfizer to commercialize CD228V in a licensing deal worth over $1 billion plus royalties.",
                "category": "company",
                "datetime": 1788441465,
                "headline": "Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion"
              },
              {
                "id": 141402549,
                "url": "https://finnhub.io/api/news?id=f473909c9b932d7403a056ae74df75d93def4694836ddacb2867be2cb41d6c19",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "https://www.sec.gov/Archives/edgar/data/1997296/000106299326004806/form8k.htm",
                "category": "company",
                "datetime": 1788425225,
                "headline": "Medicus Pharma Announces Co-Development And License Agreement With Pfizer For CD228-Targeting ADC PF-08046031, Paying $12M Upfront And $15M In One Year; Pfizer Eligible For Over $1B In Milestones Plus Royalties"
              },
              {
                "id": 141395432,
                "url": "https://finnhub.io/api/news?id=03c9adcf8e3d1f13805545b15f25bf91f5c378ae6fd56b650d6edaa8e3b77049",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer, GitLab, and Conoco Phillips shares surged to 52-week highs on Wednesday amid a series of positive company catalysts and optimistic Wall Street coverage.",
                "category": "company",
                "datetime": 1788411118,
                "headline": "Why Did PFE, GTLB, COP Stocks Jump To 52-Week Highs Today?"
              },
              {
                "id": 141383190,
                "url": "https://finnhub.io/api/news?id=e182a95e4d7485d608c506c8aecbe8a87907d1a5ebf54cdfe6b70212d13d5007",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The real bet is on what lies beyond this year's performance: a pipeline that could change everything.",
                "category": "company",
                "datetime": 1788382536,
                "headline": "Amgen Stock Signals Its Confidence. The Market Agrees."
              },
              {
                "id": 141381106,
                "url": "https://finnhub.io/api/news?id=d8961c4d829e9d325fcac0fb8349ddcb2e5e254984caa87dce84e09dcf87849a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The company is coming back into the spotlight thanks to recent developments.",
                "category": "company",
                "datetime": 1788381000,
                "headline": "Is BioNTech Stock a No-Brainer Buy on the Dip?"
              },
              {
                "id": 141379804,
                "url": "https://finnhub.io/api/news?id=1068877da71e0248a9f9d2b542c831edb89a1c42bb5b6a27d17dc6d80c2f54a4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Management's story has pivoted from concrete wins today to a distant, AI-powered future, a move that coincides with declining revenue in its core business.",
                "category": "company",
                "datetime": 1788376747,
                "headline": "Can AI Save Pfizer Stock Before Its Patent Cliff Hits?"
              },
              {
                "id": 141379806,
                "url": "https://finnhub.io/api/news?id=b1781c85eaf7a705c797d27aeb7a35ed010cf054d284ad5864f527c22ab3984e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "With central banks lifting interest rates to tackle inflation, investors are hunting for themes that do not rely purely on cheap money to grow. Artificial intelligence in healthcare is one such story. It focuses on software and data rather than heavy assets. This article highlights three Transformative AI Healthcare Stocks from our screener that apply algorithms to diagnostics, treatment decisions, and hospital efficiency. The three stocks that follow are only a starting sample from this...",
                "category": "company",
                "datetime": 1788376349,
                "headline": "3 AI Stocks To Watch With Up To 45% Earnings Growth"
              },
              {
                "id": 141379805,
                "url": "https://finnhub.io/api/news?id=0550aed9b9fb4e3815e29b2dfaee852b066b322d867b3b4a3259c261c2fe51dc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Patient investors who buy the stock may be rewarded over the long term.",
                "category": "company",
                "datetime": 1788373200,
                "headline": "Should You Buy Pfizer Stock Below $30?"
              },
              {
                "id": 141379513,
                "url": "https://finnhub.io/api/news?id=b83ed80afcb80cbd4652b6ca44f619ec245ce1285bf164a2fe2279ae839bfc54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Before the eighty-five percent surge, the company's pipeline story was getting louder just as its revenue trajectory was getting quieter.",
                "category": "company",
                "datetime": 1788373011,
                "headline": "How Did Merck Stock Beat The Market With Slowing Sales?"
              },
              {
                "id": 141379100,
                "url": "https://finnhub.io/api/news?id=ba344e7e9fad5542d2e3b8d26bb30984286ca9330384073b96967b901db86e00",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Wednesday and discover the stocks that are dominating the trading activity and setting the pace for the market.",
                "category": "company",
                "datetime": 1788372301,
                "headline": "Wednesday's session: most active stock in the S&P500 index"
              },
              {
                "id": 141379441,
                "url": "https://finnhub.io/api/news?id=62e773579e3a62df81afcdad4037a0fd886c9dbd055e0ac4c015a53682f0fe97",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The market is obsessed with a handful of hyperscalers, but the real story might be the thousands of customers you've never heard of.",
                "category": "company",
                "datetime": 1788369887,
                "headline": "Beyond The Cloud Giants: What Could Power NVIDIA Stock From Here?"
              },
              {
                "id": 141379809,
                "url": "https://finnhub.io/api/news?id=27c627420a301c328f07aa2ff7213289779a4ca998e46ffad2d56f041f875d36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Alteogen's platform can turn intravenous biologics into injections, but payments depend on multiple products reaching milestones.",
                "category": "company",
                "datetime": 1788368568,
                "headline": "Novartis Rises as $3.22 Billion Deal Targets Faster Drug Delivery"
              },
              {
                "id": 141379734,
                "url": "https://finnhub.io/api/news?id=a034ee7c5d4c02063349fe11edb654779f3be525a8c9ca656e31aedd0a6bd4ab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "TG4050 as a single agent has the potential to prevent recurrence in head and neck cancer Peer-reviewed publication in Nature Communications highlights the Phase 1 clinical and translational findings, including durable neoantigen-specific T cell responses Together, the long-term clinical and translational data further strengthen confidence in Transgene’s individualized neoantigen therapeutic vaccine approach and myvac® platform Strasbourg, France & Tokyo, Japan, September 2, 2026, 6:00 p.m. CET –",
                "category": "company",
                "datetime": 1788368400,
                "headline": "Transgene and Nec Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications"
              },
              {
                "id": 141379527,
                "url": "https://finnhub.io/api/news?id=2c4bf2f82b092b986fc284628cbe56ac62dcb5dd94015d2f4f05a066415ae9af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Johnson & Johnson (JNJ) is positioned for accelerating growth, supported by a strong pharma pipeline",
                "category": "company",
                "datetime": 1788367729,
                "headline": "Johnson & Johnson's Drug Pipeline Supports Growth Outlook, UBS Securities Says"
              },
              {
                "id": 141379763,
                "url": "https://finnhub.io/api/news?id=d39d7562cb39bbeb0067b56168aa2d838ec55efa07037265475d179865517d90",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "SOPHIA ANTIPOLIS, France, September 02, 2026--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, \"Median\" or the \"Company\"), developer of eyonis®, a suite of AI-powered Software as Medical Devices (SaMD) for the early detection and diagnosis of cancers, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced that its Board of Directors has formed a Strategic Review Committee (the \"SRC\")",
                "category": "company",
                "datetime": 1788367500,
                "headline": "Median Technologies Announces Formation of Strategic Review Committee and R&D Committee to Unlock Intrinsic Value and Accelerate Its eyonis® Pan-Cancer Strategy"
              },
              {
                "id": 141379813,
                "url": "https://finnhub.io/api/news?id=83de2d5643670260634bd9f38ff7a0c2c68e0ee39746f5f03d61f32ae1dc82cb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Alumis' (ALMS) share price drop after the disappointing results of a phase 2b trial of envudeucitini",
                "category": "company",
                "datetime": 1788367237,
                "headline": "Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says"
              },
              {
                "id": 141379814,
                "url": "https://finnhub.io/api/news?id=6b00a4516b3e19a233746fe9980cd764aa349b0f4f071857b1142b66c92d7560",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "PAHC vs. LMAT: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1788367204,
                "headline": "PAHC or LMAT: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 141379815,
                "url": "https://finnhub.io/api/news?id=56f90104fd4ff7329e171f9cfdc9a4d76025e0f0e5b7970329344eb7e3180e2e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "MKSI vs. HOCPY: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1788367203,
                "headline": "MKSI or HOCPY: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 141379816,
                "url": "https://finnhub.io/api/news?id=819a041077d747de9514891a7a8d48c4ce98210486c4299517df7996e088af63",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Since April 2026, Silchester has had a number of discussions with the Company. Silchester has come to hold serious concerns about the Company's fundamental attitude toward its shareholders. Accordingly, on 2 September 2026, Silchester formally demanded, pursuant to Article 297, Paragraph 1 of the Companies Act, that the Company convene an extraordinary general meeting of shareholders (the \"EGM\") to consider the four proposals summarised below. Silchester has asked that the EGM be held no later t",
                "category": "company",
                "datetime": 1788366960,
                "headline": "Silchester International Investors - Press Release and EGM Demand Letter - Medipal Holdings Corporation (7459:JT)"
              },
              {
                "id": 141379764,
                "url": "https://finnhub.io/api/news?id=91d2f15314fb184cb3a1823c597005aa3f73ebac151f5b1428903e1e3be8328c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Shareholders of PacBio would probably like to forget the past six months even happened. The stock dropped 20.5% and now trades at $1.29. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.",
                "category": "company",
                "datetime": 1788366743,
                "headline": "3 Reasons to Sell PACB and 1 Stock to Buy Instead"
              },
              {
                "id": 141379713,
                "url": "https://finnhub.io/api/news?id=86e15f8323c03c1ac87c4de0202df6bd8977a871e3b91cae624801d8ffb2b26d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "MMSI's broad portfolio, R&D investments and WRAPSODY opportunity support growth, while tariffs, China pressure and competition remain risks.",
                "category": "company",
                "datetime": 1788366660,
                "headline": "Here's Why You Should Add Merit Medical Stock to Your Portfolio Now"
              },
              {
                "id": 141379819,
                "url": "https://finnhub.io/api/news?id=a64fdd4280f1952b130f8c25d1558be0be050e099e1a656cc74a708d86298213",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788366612,
                "headline": "Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?"
              },
              {
                "id": 141379821,
                "url": "https://finnhub.io/api/news?id=05be3e1dbb863ad106435889fa84b14e5afd6eb53b86efc7aab48297653ce1d5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788366608,
                "headline": "Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?"
              },
              {
                "id": 141379820,
                "url": "https://finnhub.io/api/news?id=8fa0ac4ea79a3ab4284357ac2c0792a7e90742679a51f5d9a0dfc17dbee46488",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788366608,
                "headline": "Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?"
              },
              {
                "id": 141376215,
                "url": "https://finnhub.io/api/news?id=f446024cbb6f3007b0f1117b457565e027a4cd3bb605c110b389b369c3ceefdb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "PASADENA, Calif., September 02, 2026--ExchangeRight has announced the full subscription of Net-Leased Portfolio 74 DST.",
                "category": "company",
                "datetime": 1788361320,
                "headline": "ExchangeRight Fully Subscribes $63.34 Million Net-Leased Portfolio 74 DST"
              },
              {
                "id": 141376734,
                "url": "https://finnhub.io/api/news?id=92afd32f3692cb079cd0baa7d6bf71a64ca803b81564711a98ceead517051f98",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "PACS Group, Inc. (NYSE:PACS) shares rose 3.",
                "category": "company",
                "datetime": 1788361129,
                "headline": "PACS Group Shares Rise 3.3% as Company Plans Florida Expansion and Completes More Eduro Acquisitions"
              },
              {
                "id": 141376735,
                "url": "https://finnhub.io/api/news?id=8f2dd41fee60f63e80b68e904f0fcdacabc50151f1c25f0568b40400be52a8d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Telix Pharmaceuticals Ltd ADR (NASDAQ:TLX) shares rose 5. 3% in premarket trading on Wednesday as investors assessed the company’s Phase 3 BiPASS trial progress and its regulatory pathway in the U.",
                "category": "company",
                "datetime": 1788360974,
                "headline": "Telix Pharmaceuticals Shares Rise 5.3% as Analyst Highlights BiPASS Trial and FDA Pathway"
              },
              {
                "id": 141376736,
                "url": "https://finnhub.io/api/news?id=fa11b93862da7af8ae7bb08ba416fa33f24c24819640439b1e03b7a8e5a8e884",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Definitive Healthcare Corp. (NASDAQ:DH) shares rose 13% on Wednesday after Advent International submitted a non-binding proposal to acquire shares and units it does not already own for $1.",
                "category": "company",
                "datetime": 1788360916,
                "headline": "Definitive Healthcare Shares Rise 13% After Advent International Submits $1.02-Per-Share Proposal"
              },
              {
                "id": 141376199,
                "url": "https://finnhub.io/api/news?id=8516fefd2a35173aa62476707580400a1db2e41384346018cfcd8590df085ca6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls",
                "category": "company",
                "datetime": 1788360888,
                "headline": "Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls"
              },
              {
                "id": 141376374,
                "url": "https://finnhub.io/api/news?id=2a8979039ebaaf7b6d5392f1bc96fe416ee0d3b60acb0bf2b886e385d84c6bdf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "JNJ faces Stelara and upcoming drug LOEs, MedTech weakness and talc litigation, but targets accelerated growth in 2026 and beyond.",
                "category": "company",
                "datetime": 1788360420,
                "headline": "J&J Faces Multiple Headwinds: Can the Healthcare Giant Sustain Growth?"
              },
              {
                "id": 141376481,
                "url": "https://finnhub.io/api/news?id=c5142c9c5bbbb3009728f0775ed74e8ff2bb7da9ccaf6344e74f6c3910f5200e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "CNC's 117% rally now has support from improving margins, firmer pricing and higher earnings expectations, while valuation remains below key peers.",
                "category": "company",
                "datetime": 1788360360,
                "headline": "Centene Stock Roars Back 117% in a Year: Is CNC Still a Buy?"
              },
              {
                "id": 141376742,
                "url": "https://finnhub.io/api/news?id=6357db02e9beba73d4a317034c225b13d7068feb02e840788847e2ae69d50324",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
                "category": "company",
                "datetime": 1788360003,
                "headline": "Is Henry Schein (HSIC) Stock Undervalued Right Now?"
              },
              {
                "id": 141376740,
                "url": "https://finnhub.io/api/news?id=e70babfe4434431c59cbf62fe3658bc78e61c69d957684594ba45ab3c28449b8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
                "category": "company",
                "datetime": 1788360003,
                "headline": "Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?"
              },
              {
                "id": 141376484,
                "url": "https://finnhub.io/api/news?id=2e6e6eb86cdb065fda7ccb0f0e43c1db1ecf111902d18bce3f6ad9f110cb32fd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
                "category": "company",
                "datetime": 1788360003,
                "headline": "Is Centene (CNC) a Great Value Stock Right Now?"
              },
              {
                "id": 141376744,
                "url": "https://finnhub.io/api/news?id=66691761802609441f493193bf0eebd8332d62c66f25f2be8f452cb96b662ab7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Here is how Cronos Group (CRON) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.",
                "category": "company",
                "datetime": 1788360002,
                "headline": "Are Medical Stocks Lagging  Cronos Group (CRON) This Year?"
              },
              {
                "id": 141376743,
                "url": "https://finnhub.io/api/news?id=7eefbcb4a746b8db8af0c70c0ed582b7289f2150b2dfc9ab3101b2afb4d49b80",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
                "category": "company",
                "datetime": 1788360002,
                "headline": "Should Value Investors Buy Phibro Animal Health (PAHC) Stock?"
              },
              {
                "id": 141376482,
                "url": "https://finnhub.io/api/news?id=1a4613cd03f70ab7ef59b4a3fe7536a4e0afc75b3ce0973c5e18e4e6f7c44109",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The average brokerage recommendation (ABR) for UnitedHealth (UNH) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
                "category": "company",
                "datetime": 1788359403,
                "headline": "Brokers Suggest Investing in UnitedHealth (UNH): Read This Before Placing a Bet"
              },
              {
                "id": 141376747,
                "url": "https://finnhub.io/api/news?id=37c7158357ab99e44f9f8448025402357ba5e342316478203340321a38629a6a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "ENSG's decentralized model is driving organic growth through higher occupancy, stronger clinical results and improved productivity across its facilities.",
                "category": "company",
                "datetime": 1788359100,
                "headline": "Can Ensign Group's Operating Model Drive Growth Beyond Acquisitions?"
              },
              {
                "id": 141376748,
                "url": "https://finnhub.io/api/news?id=2bb6090fbc1907fa07166d09c465dee1724d2d4a211bd228699401558f43aa38",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AstraZeneca reports positive SANOVO data, showing Tagrisso plus Orpathys improved PFS in first-line EGFR-mutated NSCLC.",
                "category": "company",
                "datetime": 1788358800,
                "headline": "AZN's Tagrisso Plus Orpathys Study in First-Line NSCLC Meets Goal"
              },
              {
                "id": 141376402,
                "url": "https://finnhub.io/api/news?id=4f01b18ba061694907d58ff1e3e358c9247e7ea3c97f3ad7eb845610022a808d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Medtronic, McCormick and T. Rowe Price are among the stocks that have outperformed the S&P 500 over the past three months—and have dividend yields of at least 3%.",
                "category": "company",
                "datetime": 1788358620,
                "headline": "6 Safe Dividend Aristocrats Yielding Up to 4.7% to Buy as Tech Cools Off"
              },
              {
                "id": 141376750,
                "url": "https://finnhub.io/api/news?id=42a0002644172783d8213beb012f040e7c4480ebe809664ef6e240172ae03de0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "This Strategic Engagement is Designed to Strengthen NeuroThera's U.S. Market Position, Visibility Among Key U.S. Federal Stakeholders, Reinforce the Clinical and PublicHealth Importance of Advancing New Treatment Options for Adult Tourette Syndrome T...",
                "category": "company",
                "datetime": 1788358611,
                "headline": "SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies"
              },
              {
                "id": 141376751,
                "url": "https://finnhub.io/api/news?id=d118cf1ab3728ebf1b85979981ec53e439dc21f0386a451d7ff93199e67f6195",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The recent breakout of Moderna reminded investors that AI stocks aren’t the only destination to make money. Healthcare and biotech stocks offer promising long-term opportunities if chosen wisely. We ran an analysis based on Insider Monkey’s proprietary database of over 900 hedge funds to see which healthcare stocks trading under $20 billionaire-led funds were holding […]",
                "category": "company",
                "datetime": 1788358558,
                "headline": "Billionaire Portfolios: 2 Under-$20 Healthcare Stock Picks"
              },
              {
                "id": 141376752,
                "url": "https://finnhub.io/api/news?id=23b7e788525c1705550d4bcef5cde56b81ab719516c7993a2cc9374c07ce1061",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "FRAMINGHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- The special committee (the “Special Committee”) of the Board of Directors of Definitive Healthcare Corp. (the “Company”) (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced that it has received a non-binding indication of interest (the “Proposal”), dated as of September 1, 2026, from Advent International, L.P., on behalf of certain of its managed funds (collectively, “Advent”), to acquire all of the outst",
                "category": "company",
                "datetime": 1788358500,
                "headline": "Special Committee of Definitive Healthcare Board Confirms Receipt of Going-Private Proposal from Advent International"
              },
              {
                "id": 141376642,
                "url": "https://finnhub.io/api/news?id=63ba4aeafdabf70c656cfa129a74485a7db50be29aa74278a014142c21e74106",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "RUTHERFORD, N.J., & LA JOLLA, Calif., September 02, 2026--Lōkahi Therapeutics™ expands its ai² Futures Lab™ network through a collaboration with SDSU Fowler College of Business to identify therapeutic assets.",
                "category": "company",
                "datetime": 1788358500,
                "headline": "Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Collaboration with San Diego State University Fowler College of Business"
              },
              {
                "id": 141377997,
                "url": "https://finnhub.io/api/news?id=7b8758e202d8fe4bd88cfec11ba4a82a644d1cfb2b78e14289edbb9e15347d28",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2161979533/image_2161979533.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Clinuvel Pharmaceuticals Limited analysis: SCENESSE profits, A$252M cash/no debt, and CUV105 vitiligo trial catalyst vs AbbVie/Pfizer risks—click for more on CUVL.",
                "category": "company",
                "datetime": 1788347567,
                "headline": "5 Reasons To Buy Clinuvel Pharmaceuticals After Its Nasdaq Uplisting"
              },
              {
                "id": 141373298,
                "url": "https://finnhub.io/api/news?id=f7e2cfc949a0d7d1fb182ebe8905cbc49089d1031cfcb1d4a54eb966212ccbe1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "GSK (LSE:GSK) is back in focus after presenting positive phase II data for its mRNA seasonal flu vaccine and confirming plans to start a phase III trial in September 2026, following Fast Track designation in the US. Against this backdrop of pipeline news, GSK’s share price has shown mixed short term momentum, with a 1-day share price return of 0.97% but a 30-day share price return that is down 3.11%, while the 1-year total shareholder return of 34.36% points to much stronger longer term...",
                "category": "company",
                "datetime": 1788318778,
                "headline": "GSK (LSE:GSK), What Is Behind The Latest Attention?"
              },
              {
                "id": 141373023,
                "url": "https://finnhub.io/api/news?id=e3266eba8d7c7f32c4ee173ae3bfd8a04ad772c1b53d5cd7267bcbf9be985087",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Johnson & Johnson (NYSE: JNJ) was found liable by a Louisiana jury in a high-profile talc-related mesothelioma case, adding a fresh verdict to its ongoing talc litigation. The jury decision centers on alleged asbestos exposure from Johnson & Johnson talc products and raises questions about potential future legal costs for the company. This verdict contributes to the broader legal overhang that investors weigh alongside Johnson & Johnson's core healthcare operations and balance sheet...",
                "category": "company",
                "datetime": 1788318651,
                "headline": "Does Johnson & Johnson (JNJ) Talc Verdict Add To Its Legal Risk?"
              },
              {
                "id": 141373039,
                "url": "https://finnhub.io/api/news?id=afa65034f7579432b1d57502c780d52f8dd164c949fe1c6d378dc4be79a5acc5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "In August 2026, Merit Medical Systems announced that Sheri Lewis would join as Executive Vice President of Global Operations, bringing three decades of global manufacturing and supply chain experience from SkinHealth Systems, Avantor, Medtronic, and Honeywell, while long-time operations leader Mr. Peterson shifted to a Senior Advisor role through March 2027 to support continuity. This leadership transition highlights Merit's focus on strengthening global operations and supply chain...",
                "category": "company",
                "datetime": 1788314870,
                "headline": "How Investors Are Reacting To Merit Medical Systems (MMSI) New Global Operations Leadership Transition"
              },
              {
                "id": 141373301,
                "url": "https://finnhub.io/api/news?id=24eef22228eed8ffbd8091caadf478dcbe7eea4e653e52b0d457f9066f730f6f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Vertex Pharmaceuticals stock has delivered strong multi year gains, and current valuation checks suggest the shares now look closer to fairly priced than clearly cheap or clearly expensive. Vertex Pharmaceuticals has returned 184.9% over the past 5 years, which puts extra focus on whether the current price still offers an appealing entry point for new money. Expectations for continued revenue and cash flow growth from its existing treatment portfolio can support today’s valuation, while any...",
                "category": "company",
                "datetime": 1788314840,
                "headline": "Vertex (VRTX) Stock Trades At A Premium On Earnings Yet Looks Fair On Broader Checks"
              },
              {
                "id": 141373302,
                "url": "https://finnhub.io/api/news?id=66e099b1e7da169967624de7aedb9f6901aa6034b42d3bcd2a797f9766d16602",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Two of healthcare’s most pressing challenges - the growing prevalence of diabetes and rising antibiotic resistance - are converging in diabetic foot infections, where slow-healing wounds can develop into serious infections, hospitalisation and amputation. The International Diabetes Federation...",
                "category": "company",
                "datetime": 1788313140,
                "headline": "Recce Pharmaceuticals advances R327 as diabetes and antibiotic resistance burdens converge"
              },
              {
                "id": 141373098,
                "url": "https://finnhub.io/api/news?id=3b8ae9abd0431d10053f8279b998a980036723c7d887184dd5f43c60a6006a14",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "In August 2026, Merck & Co., Inc. and Moderna, Inc. reported that their Phase 3 INTerpath-001 trial of individualized mRNA therapy intismeran autogene plus KEYTRUDA in completely resected stage IIB–IV melanoma met its primary and key secondary endpoints, improving recurrence-free and distant metastasis-free survival versus KEYTRUDA alone with no new safety issues identified. This marks the first positive Phase 3 outcome for both an individualized neoantigen therapy and an mRNA-based cancer...",
                "category": "company",
                "datetime": 1788311942,
                "headline": "Did Merck’s (MRK) First Positive Phase 3 Individualized mRNA Cancer Trial Just Redefine Its Moat?"
              },
              {
                "id": 141373304,
                "url": "https://finnhub.io/api/news?id=69b7472681737818ebf952176673daae5b1fc9ae52427b529f40bbcfd12ffb45",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The selloff followed topline results from the Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus, or SLE, a chronic autoimmune disease in which the body's immune system mistakenly attacks healthy tissues.",
                "category": "company",
                "datetime": 1788310512,
                "headline": "ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff?"
              },
              {
                "id": 141373305,
                "url": "https://finnhub.io/api/news?id=9938a6ed856998287cea2992d204673e307eddab99bfdaf3d24d3141ba6cb2df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Henry Schein stock performance snapshot Henry Schein (HSIC) stock has drawn investor attention after recent share price moves, with the company reporting positive total returns over the past year and across multi year periods, alongside reported revenue and net income growth. At the latest share price of US$88.52, Henry Schein has given investors a 16.9% share price return over the past 90 days and a 29.4% total shareholder return over the past year. This suggests momentum has been building...",
                "category": "company",
                "datetime": 1788307678,
                "headline": "Henry Schein (HSIC) Looks Modestly Undervalued, Is More Upside Still Available?"
              },
              {
                "id": 141373306,
                "url": "https://finnhub.io/api/news?id=1d72c9067f702f968a1215373b804800c6ba313a63ace7b0e34fb6978b6dfbed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Protagonist Therapeutics stock has delivered very strong returns over the past few years, yet the broader valuation checks currently lean toward the shares looking expensive rather than like an obvious bargain. After such a strong move, investors are weighing how much of the good news is already reflected in the price. Over the past 3 years, Protagonist Therapeutics has gained roughly 6.5 times its earlier level. This puts extra focus on whether recent enthusiasm has pushed the valuation...",
                "category": "company",
                "datetime": 1788307621,
                "headline": "Protagonist Therapeutics (PTGX) Stock Could Be Overvalued Following FDA Approval News"
              },
              {
                "id": 141373307,
                "url": "https://finnhub.io/api/news?id=188bb6b727ebbe4cb6585f90cb7bb0c7c4c2c6b86cf7eb77b011a3aef842952d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and meta",
                "category": "company",
                "datetime": 1788307200,
                "headline": "Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange"
              },
              {
                "id": 141373308,
                "url": "https://finnhub.io/api/news?id=c570bd23c058b035d332a00ebe305036a196042744618ec3070b47a97d47c8e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Common shares to trade in the U.S. under new ticker ZTEKF beginning September 2, 2026Guelph, Ontario--(Newsfile Corp. - September 1, 2026) - Zentek Ltd. (TSXV: ZEN) (OTCQX: ZTEKF) (\"Zentek\" or the \"Company\") today announces, further to its news releases dated August 28, 2026, and August 31, 2026, that its common shares have been approved for trading on the OTCQX Best Market, the highest tier of the OTC Markets, and will begin trading under the symbol \"ZTEKF\" at the open of trading on Wednesday,.",
                "category": "company",
                "datetime": 1788305400,
                "headline": "Zentek Approved for Trading on the OTCQX Best Market"
              },
              {
                "id": 141373216,
                "url": "https://finnhub.io/api/news?id=03894c6e2cdf811c471dd5a3d8ab482cba7329fe87632ef9a99d640e5cac5ea2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Home care revenue surged 15.2% as sales rep productivity hit record levels.",
                "category": "company",
                "datetime": 1788305297,
                "headline": "Electromed (ELMD) Q4 2026 Earnings Call Transcript"
              },
              {
                "id": 141373310,
                "url": "https://finnhub.io/api/news?id=405b8906cdcf4ce2ecc795723bb2d54da4f33fdaa2492fe45bde7e39e0c53778",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment of 350 patients.Telix has positively engaged with the FDA on a New Drug Application (NDA) pathway in the U.S. that would support new product reimbursement and broaden access to 68Ga-PSMA-PET imaging across a significantly larger patient population.BiPASS is designed to evaluate the diagnostic performance of 68Ga-PSMA-11 PET combined with MRI for the detection of pro",
                "category": "company",
                "datetime": 1788304680,
                "headline": "Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway"
              },
              {
                "id": 141373311,
                "url": "https://finnhub.io/api/news?id=8057f6f0bb4433460065383e1dd0424dbd9e0cd6492588fb79adb27c944da47f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "EAGLE, Idaho, Sept. 01, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, announced today that it will participate in the upcoming 2026 Jefferies Healthcare Services Conference on September 15, 2026. Brent Guerisoli, Chief Executive Officer and John Gochnour, President and Chief Operating Officer, will participate in a fireside chat on September 15, 2026 at 3:00 p.m. Central Tim",
                "category": "company",
                "datetime": 1788304020,
                "headline": "Pennant Group to Participate in the 2026 Jefferies Healthcare Services Conference"
              },
              {
                "id": 141373312,
                "url": "https://finnhub.io/api/news?id=86efe8a544b056ba673a7a56ff828552c93c09cc25bb77cf3d8740408a14a094",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Dogwood Therapeutics (NASDAQ:DWTX) said its Phase 2b study of Halneuron, an investigational treatment for chemotherapy-induced neuropathic pain, has enrolled more than 230 patients and is expected to report top-line data later this fall. During a virtual key opinion leader event, Chief Executive Of",
                "category": "company",
                "datetime": 1788303718,
                "headline": "Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment"
              },
              {
                "id": 141373313,
                "url": "https://finnhub.io/api/news?id=616e0a2cb20515a31530c13b22d9de7197ef6d02c68f89688bd3198063b25cc2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Tilray Brands, Inc. (TLRY) concluded the recent trading session at $4.5, signifying a -1.53% move from its prior day's close.",
                "category": "company",
                "datetime": 1788303602,
                "headline": "Tilray Brands, Inc. (TLRY) Declines More Than Market: Some Information for Investors"
              },
              {
                "id": 141373314,
                "url": "https://finnhub.io/api/news?id=dafdac452e37360d95f904a33b998e0f8bfb91acc50892f880bfe7964ca7d267",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "MONTREAL, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (\"Knight\") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has received regulatory approval from INVIMA, the Colombian health regulatory agency, for TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response, loss of response, or intolerance to prior treatment with corticosteroids and intr",
                "category": "company",
                "datetime": 1788303600,
                "headline": "Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Colombia"
              },
              {
                "id": 141373021,
                "url": "https://finnhub.io/api/news?id=3ce8b5938764a357861e6e95bde47d6bc604547fcc33b8ddc652c6a7c1def557",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Johnson & Johnson (JNJ) closed at $271.19 in the latest trading session, marking a +2.01% move from the prior day.",
                "category": "company",
                "datetime": 1788302702,
                "headline": "Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts"
              },
              {
                "id": 141373031,
                "url": "https://finnhub.io/api/news?id=a283f548e6b695db6b53c9431e83314907495021fcfff28b54da98936332d754",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Burry followed a simple trade management rule.",
                "category": "company",
                "datetime": 1788301980,
                "headline": "Michael Burry takes money off the table after stock nearly doubles"
              },
              {
                "id": 141373317,
                "url": "https://finnhub.io/api/news?id=ded2ad67c9e139b7de51ed6a8abea8af32fdc5bcc04e11195a20d9b827c3f671",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Fractyl Health (NASDAQ:GUTS) outlined a commercial strategy for its investigational Revita procedure, positioning the one-time endoscopic therapy as a potential option for patients seeking to maintain weight loss after discontinuing GLP-1 medicines. The company said Revita is designed for post-GLP-",
                "category": "company",
                "datetime": 1788300118,
                "headline": "Fractyl Health Eyes 2028 Revita Launch for Post-GLP-1 Weight Maintenance"
              },
              {
                "id": 141369450,
                "url": "https://finnhub.io/api/news?id=f6df96d9207a69f3bd85a79efc10b1a46708ee298f9bd585bddd15eb74d1e65c",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest.",
                "category": "company",
                "datetime": 1788285901,
                "headline": "Curious about the most active S&P500 stocks in today's session?"
              },
              {
                "id": 141361968,
                "url": "https://finnhub.io/api/news?id=e96871172873d0ee356a7582203752db199b30a6eb4d6edec1aa55a84808e45f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "New molecular imaging capabilities connect longitudinal radiopharmaceutical uptake with biodistribution, efficacy and clinically annotated PDX tumor biology in a single, U.-based workflowHACKENSACK, NJ / ACCESS Newswire / September 1, 2026 / , a leading provider of translational oncology research solutions, today announced the expansion of its integrated radiopharmaceutical development platform with new in-house SPECT/CT imaging capabilities.",
                "category": "company",
                "datetime": 1788271200,
                "headline": "Champions Oncology Expands Integrated Radiopharmaceutical Development Platform with In-House SPECT/CT Imaging"
              },
              {
                "id": 141361086,
                "url": "https://finnhub.io/api/news?id=e02d9d486b74742abd985864b55aba9706ff93090b48a3332db609d16f1b8466",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Three blue-chip CFO swaps touched off double-digit stock rallies while Rivian's announcement landed with a thud. The difference comes down to one decision Rivian has yet to make.",
                "category": "company",
                "datetime": 1788269747,
                "headline": "CFO Turnover at AT&T, Caterpillar, and Pfizer Sparked Rallies. Here’s Why Rivian’s Didn’t."
              },
              {
                "id": 141361969,
                "url": "https://finnhub.io/api/news?id=a3d2bd9e2e7a1563d69ec569a40caaa48e51f2d5ae1a31d54ca6f34cc56f0cce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Company to Present and Host 1x1 Investor Meetings on Tuesday and Wednesday, September 15th-16th, 2026 FocalTherics™ to Present at the H.C. Wainwright 28th Annual Global Investment Conference Company to Present and Host 1x1 Investor Meetings on Tuesday and Wednesday, September 15th-16th, 2026 AUSTIN, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced that Ryan Rhodes, Chief Executive Officer, is schedul",
                "category": "company",
                "datetime": 1788265800,
                "headline": "FocalTherics™ to Present at the H.C. Wainwright 28th Annual Global Investment Conference"
              },
              {
                "id": 141361973,
                "url": "https://finnhub.io/api/news?id=0130ee39f7dfd1f43695963ea74fc623b987ab75d42d7dd455164ebada20aee6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 1 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in September.",
                "category": "company",
                "datetime": 1788264000,
                "headline": "Immunocore to present at upcoming investor conferences"
              },
              {
                "id": 141361972,
                "url": "https://finnhub.io/api/news?id=53514359c8a54fb77d1df18bf3175c766b9cd23916db7c0f57d85b3eadc7a2af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "NASHVILLE, Tenn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following three investor conferences in September in New York, NY: 2026 Cantor Global Healthcare Conference Format: Fireside chat + 1x1 investor meetingsDate/Time: Wednesday, September 9, 2026, at 1:35 p.m. ET Lake Street Capital Markets 10th Annual Best Ideas Growth Conference Format: 1",
                "category": "company",
                "datetime": 1788264000,
                "headline": "Harrow to Participate in Three Investor Conferences in September"
              },
              {
                "id": 141361971,
                "url": "https://finnhub.io/api/news?id=068d1188e6a5b78f43a72199c6a68e9fce37d4d5912d89540eeb6b71bdd641de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "– Following productive FDA discussions, Upstream Bio will study 400 mg of verekitug administered every 12 weeks, versus placebo, in severe asthma and CRSwNP with one pivotal Phase 3 trial in each indication – – The Company’s Phase 3 strategy is designed to deliver best-in-class efficacy across both indications by evaluating a high-dose, quarterly regimen of verekitug in broad patient populations – – The Company remains on track to initiate both Phase 3 trials in Q1 2027 – WALTHAM, Mass., Sept. 0",
                "category": "company",
                "datetime": 1788264000,
                "headline": "Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP"
              },
              {
                "id": 141361970,
                "url": "https://finnhub.io/api/news?id=5db9a115014cd42847d1c40f745401c79a4923d7fc362fbfe875d08c6bcd5059",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "WILMINGTON, Del., September 01, 2026--AstraZeneca today announced the successful completion of the previously announced exclusive license agreement with Dizal Pharmaceutical Co., Ltd for ZEGFROVY® (sunvozertinib), an oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer. Through this agreement, AstraZeneca has acquired worldwide rights to develop and commercialize ZEGFROVY.",
                "category": "company",
                "datetime": 1788264000,
                "headline": "AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer"
              },
              {
                "id": 141360929,
                "url": "https://finnhub.io/api/news?id=850fd776842a9c5d07f1f1707f7c659b106fea0258106098bb8e97ec28b41bc4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.",
                "category": "company",
                "datetime": 1788261020,
                "headline": "1 Cash-Heavy Stock on Our Buy List and 2 Facing Challenges"
              },
              {
                "id": 141360369,
                "url": "https://finnhub.io/api/news?id=c1f6f6beede1420f94c162a824c404f259652bdfbddaae165962835edda18e54",
                "image": "",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "",
                "category": "company",
                "datetime": 1788254200,
                "headline": "Exelixis: \"Hold\" On Zanzalintinib Subpopulation Miss And STELLAR-304 2H 2026 Data"
              },
              {
                "id": 141369210,
                "url": "https://finnhub.io/api/news?id=0d04aa19727a244ddc1f76bb0dd9b5cf3d4e611738ede8d0b549133616d1c919",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/01/United-States-President-Donald-Trump-at-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Trump secures drug pricing deals with nine pharma companies as Kennedy reveals intense pressure from the President to deliver.",
                "category": "company",
                "datetime": 1788238659,
                "headline": "Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President"
              },
              {
                "id": 141361975,
                "url": "https://finnhub.io/api/news?id=20f6c0ad23b56a9f40452917e323e7d70442f17e0b5a5d112aa3fff69a505688",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "MENLO PARK, Calif., August 31, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for the treatment of polycythemia vera (PV), will be presented at the Society of Hematologic Onco",
                "category": "company",
                "datetime": 1788217200,
                "headline": "AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting"
              },
              {
                "id": 141361962,
                "url": "https://finnhub.io/api/news?id=1eb020282d63561578c91813d292244c3487cb4cbce6213ce0b6ea900ac49ef7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (NYSE:PFE) has reached a confidential settlement covering federal lawsuits over its Depo-Provera contraceptive and alleged intracranial meningioma risk. The agreement reportedly addresses more than 6,000 cases, with financial terms not disclosed and no admission of liability by Pfizer. The resolution closes a multi year legal overhang tied to Depo-Provera and brings clarity to a significant product liability dispute. This kind of large scale legal settlement can shift how investors...",
                "category": "company",
                "datetime": 1788211345,
                "headline": "Pfizer (PFE) Reaches Confidential Settlement In Depo Provera Litigation"
              },
              {
                "id": 141355998,
                "url": "https://finnhub.io/api/news?id=3acb000fbcd04c48667d73cb6408b0aeb637920de5672722498fff8d7028614e",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Monday and uncover the stocks that are leading the way in terms of trading volume and market attention.",
                "category": "company",
                "datetime": 1788199500,
                "headline": "Stay informed about the most active stocks in the S&P500 index on Monday's session."
              },
              {
                "id": 141369974,
                "url": "https://finnhub.io/api/news?id=18cea28d5d210dc288668ffb7e1824889645dae50b7f28b889b84b9d79355012",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "As investors hedge against AI-trade valuation worries, dividend payers gain favor. AT&T, ONEOK, and Pfizer offer yields from 4.3% to 6.1% with distinct capital-return strategies.",
                "category": "company",
                "datetime": 1788198300,
                "headline": "3 Stocks for Investors Who Still Believe Cash Is King"
              },
              {
                "id": 141361976,
                "url": "https://finnhub.io/api/news?id=f5fc78694443af8b2ccba1f3576be74e00cfd6028a62f46eaa9ff39a9257ada3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "On Friday, the U.S. Food and Drug Administration (FDA) approved Takeda Pharmaceutical Co. Ltd.‘s (NYSE:TAK) MIMRYLO (rusfertide) for polycythemia vera, a type of blood cancer. How MIMRYLO Combats Polycythemia Vera Polycythemia vera forces the human body to overproduce red blood cells. This harmful overproduction dramatically increases blood thickness. Increased viscosity places patients at high risk for life-threatening thrombotic events, which include severe complications like strokes, pulmonar",
                "category": "company",
                "datetime": 1788197893,
                "headline": "Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug"
              },
              {
                "id": 141361469,
                "url": "https://finnhub.io/api/news?id=34e30cd031c810d63415f91661c6455830424a81e544234aa232e3fa4a773e73",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "By Mike Sheikh Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at the stock chart may miss the signs of a strategic reset orchestrated by biotech legends, and miss […] The post Cocrystal Pharma: The Strategic Reset Investors May Be Missing appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1788194343,
                "headline": "Cocrystal Pharma: The Strategic Reset Investors May Be Missing"
              },
              {
                "id": 141360884,
                "url": "https://finnhub.io/api/news?id=352ccb9dbc196e7fd72c636ec84aecaf01f3e6b3516908358b7cc115d9b040a4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "PFE's oncology growth is led by Padcev, while a broad pipeline and label expansions aim to fuel longer-term gains.",
                "category": "company",
                "datetime": 1788194220,
                "headline": "From Padcev to PF-08634404: Pfizer's Oncology Growth Push"
              },
              {
                "id": 141361964,
                "url": "https://finnhub.io/api/news?id=d687dd600920ad682d76bf754050827cfed78a5f6453da5494d582f6956ac7c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer and Starbucks both raised their outlooks this summer, but a louder recovery and a quieter one are not the same thing, and for investors who need a portfolio to fund actual withdrawals, the difference matters enormously.",
                "category": "company",
                "datetime": 1788189019,
                "headline": "Pfizer and Starbucks: One Turnaround Is Built to Last, and One Isn’t"
              },
              {
                "id": 141360941,
                "url": "https://finnhub.io/api/news?id=93daf068001f0177a626163885017d0747b3e30922e44b72d9ae6fc4a49d8e10",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "BRONX, N.Y., August 31, 2026--Cassino appointed Interim President and CEO of Oligomerix",
                "category": "company",
                "datetime": 1788189000,
                "headline": "Oligomerix Appoints Biopharmaceutical Industry Veteran Cara Cassino, M.D. as Interim President and Chief Executive Officer"
              },
              {
                "id": 141356225,
                "url": "https://finnhub.io/api/news?id=59a441525d8351f9ca682906e1f1184af38874463dd1c92a51d84c67a55ae7f7",
                "image": "",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "",
                "category": "company",
                "datetime": 1788188253,
                "headline": "Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know"
              },
              {
                "id": 141361979,
                "url": "https://finnhub.io/api/news?id=ca07fb7e6b7c73414e47b6d53d7b24cde37a40047a9f3d4708b8b0844e03c7d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "ALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, announced today that AEON management will host in-person 1x1 investor meetings at Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference being held in New York City on Thursday, September 10th, 2026",
                "category": "company",
                "datetime": 1788181200,
                "headline": "AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference"
              },
              {
                "id": 141361978,
                "url": "https://finnhub.io/api/news?id=ea9b4d428df5c1aa920883745aa938c94d6714e139b4f9a992cccd1cc8f44530",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the H.C. Wainwright 28th Annual Global Investment Conference. Dr. Mor’s prerecorded presentation will be webcast and will be available starting on September 11, 2026 at 7:",
                "category": "company",
                "datetime": 1788181200,
                "headline": "Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference"
              },
              {
                "id": 141361965,
                "url": "https://finnhub.io/api/news?id=b231148faf34ecf4376fa7cd1360ea08dcd70cb9f2ae26b85fd098d1372580d6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "PFE has underperformed the broader market over the past year, while analysts remain moderately optimistic about its future prospects.",
                "category": "company",
                "datetime": 1788178610,
                "headline": "Is Pfizer Stock Underperforming the S&P 500?"
              },
              {
                "id": 141355051,
                "url": "https://finnhub.io/api/news?id=d92b169b63df4d431d6ca4d3e2a910e2a44404564eff749693f603b009075ae3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/466613278/image_466613278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more and the picks.",
                "category": "company",
                "datetime": 1788173434,
                "headline": "Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs"
              },
              {
                "id": 141355189,
                "url": "https://finnhub.io/api/news?id=44ebe163178eaa1153c02289dc304ae0153891decf8d797882248abcbc5fa56d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/31/Kazan--Russia---August-19--2021-Take-two.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Take-Two Interactive Software, on Aug. 7, reported adjusted earnings were 35 cents per share, topping the analyst consensus of 33 cents.",
                "category": "company",
                "datetime": 1788161453,
                "headline": "Take Two Interactive, Nvidia, Cheniere Energy And A Health Care Stock: CNBC’s ‘Final Trades’"
              },
              {
                "id": 141341224,
                "url": "https://finnhub.io/api/news?id=a70f356816315e6c1cffbf3ddb6582552dedd39464f32f29f67f627611d5c738",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Dividend activity recap for Champions, Contenders & Challengers: dividend changes plus upcoming ex-dividend and pay dates. See more here.",
                "category": "company",
                "datetime": 1787954658,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week August 30"
              },
              {
                "id": 141339624,
                "url": "https://finnhub.io/api/news?id=44cf81c569d9ca518128cd7ce1b63abb0cdaab2e4a4b7891731afcb9cd738ed8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2291247270/image_2291247270.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "BioNTech SE maintains a Strong Buy rating, driven by robust late-stage oncology pipeline momentum and strategic partnerships. Click for more on BNTX.",
                "category": "company",
                "datetime": 1787933252,
                "headline": "BioNTech: Reiterating Strong Buy Based On COMIRNATY Variant Expansion And More"
              },
              {
                "id": 139934456,
                "url": "https://finnhub.io/api/news?id=188b4d8ee71a8e52b66809d406cc7c293d8b00b7f1c9f28a4df221dd0b53d09c",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "",
                "category": "company",
                "datetime": 1787922108,
                "headline": "Hesai Says Co Selected By NVIDIA As Lidar Partner For NVIDIA DRIVE Hyperion 10"
              },
              {
                "id": 141333616,
                "url": "https://finnhub.io/api/news?id=0d52f8ed9a8c55b6fd8382288f6020e1ef954f50a94ac5eebb58f2cc3e7d4667",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/27/Benzinga-Quick-Spark.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligibility for adults 65+ and those with high-risk conditions.",
                "category": "company",
                "datetime": 1787856373,
                "headline": "QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax"
              },
              {
                "id": 141333250,
                "url": "https://finnhub.io/api/news?id=c976fd558e6866e1bc656afad4fbeeca8f9842607abe130a3816721ec9602f4c",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variantsShipping will begin immediately to ensure rapid access to this season’s",
                "category": "company",
                "datetime": 1787848353,
                "headline": "FDA Approves Pfizer And BioNTech's Supplemental Biologics License Application For 2026-2027 COVID-19 Vaccine Formula"
              },
              {
                "id": 141324202,
                "url": "https://finnhub.io/api/news?id=c710f4da94ba6b1816de5555e8b2151446aae51f52ce20fa254d5a2921bdc8fd",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Stay informed about the most active stocks in the S&P500 index on Wednesday's session. Discover the stocks that are generating the highest trading volume and driving market activity.",
                "category": "company",
                "datetime": 1787767501,
                "headline": "Explore the S&P500 index on Wednesday and find out which stocks are the most active in today's session."
              },
              {
                "id": 141323879,
                "url": "https://finnhub.io/api/news?id=e494ff8179b9d0c70eba42a3a19b517dc0f4693d908e9afdf3f84acf6ae499fb",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-hiv-infection-newborns",
                "category": "company",
                "datetime": 1787672452,
                "headline": "FDA Approves Drug To Treat HIV Infection in Newborns"
              },
              {
                "id": 141316607,
                "url": "https://finnhub.io/api/news?id=f649b9f86ef6cc42c05b0e00dc7665d58e101cc4a89153527c255679d3750e45",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/25/United-States-Treasury-Check-Surrounded-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Benzinga readers can review the latest analyst takes on high-yielding stocks in health care sector. Top analysts & recent news on PRGO, PFE, BMY.",
                "category": "company",
                "datetime": 1787643564,
                "headline": "Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields"
              },
              {
                "id": 141310292,
                "url": "https://finnhub.io/api/news?id=51e21f3e9e89a69ade69beb2705a25f5ef509f927e49a56f97601ab66eb255f0",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will",
                "category": "company",
                "datetime": 1787578524,
                "headline": "10 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 141300403,
                "url": "https://finnhub.io/api/news?id=423ff622523781f562142ed7b0b7d87cfe74dfb95cf04deb4b282bc564269b75",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2286515404/image_2286515404.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Prelude Therapeutics has rebounded 500% in 12 months after a $60M option deal with Incyte for its JAK2 inhibitor program. Read why PRLD stock is a Hold.",
                "category": "company",
                "datetime": 1787464368,
                "headline": "Prelude Therapeutics: A Prognosis After Year-Long Rally"
              },
              {
                "id": 141297020,
                "url": "https://finnhub.io/api/news?id=11288d4e55ab8bdea17b48cac5b6f8da22ec3e49a92777d34caf5213b1b641d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer is facing material patent expirations over the next two years, but that will be over by 2030.",
                "category": "company",
                "datetime": 1787412900,
                "headline": "Prediction: This Is Where Pfizer Stock Will Be in 2030"
              },
              {
                "id": 141294197,
                "url": "https://finnhub.io/api/news?id=9920479acaf24aa724842791b54472c02592d99d6bd156b129117a03ccd429fb",
                "image": "",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "",
                "category": "company",
                "datetime": 1787400834,
                "headline": "Buy 4 Barron's Better Bets (Than T-Bills) Out Of 11 'Safer' August DiviDogs"
              },
              {
                "id": 141279214,
                "url": "https://finnhub.io/api/news?id=2786289cd80629a85c4beb9b2b703fa1debdc3f8f0ee3af73c8134554ef335cd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "After skyrocketing 1,027% off a low, Relay Therapeutics taps AI and machine learning to fuel more gains.",
                "category": "company",
                "datetime": 1787345039,
                "headline": "This 'Dynamo' Biotech Puts AI-Fueled Breakout In Motion"
              },
              {
                "id": 141278397,
                "url": "https://finnhub.io/api/news?id=38dd0d7e7c6eb6285ae70cc42b7302f86dda418041d32af3c76017a0115b343f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The success of Moderna and Merck’s intismeran autogene doesn’t guarantee smooth sailing for other mRNA vaccine developers",
                "category": "company",
                "datetime": 1787342040,
                "headline": "Can mRNA Cure Cancer? Inside the Pipeline Risks for Biotech’s Biggest Players"
              },
              {
                "id": 141278028,
                "url": "https://finnhub.io/api/news?id=b85cf2c4c1752d6b68a87ce0e31deed248fb731b2165e96279cc313ac08ca183",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Consensus asks Eli Lilly for far less growth than it is delivering, and for margins to keep climbing from a level it only just reached.",
                "category": "company",
                "datetime": 1787341256,
                "headline": "Lilly's Multiple Assumes Less Growth Than You Think"
              },
              {
                "id": 141279211,
                "url": "https://finnhub.io/api/news?id=ca6f2c7d9ec1e90d62aaba8967fad5a833bf772134237c2edb5e2eff87bc99f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer has been treading water for the past six months, recording a small return of 2.6% while holding steady at $27.76. The stock also fell short of the S&P 500’s 12.7% gain during that period.",
                "category": "company",
                "datetime": 1787340947,
                "headline": "2 Reasons to Watch PFE and 1 to Stay Cautious"
              },
              {
                "id": 141278037,
                "url": "https://finnhub.io/api/news?id=2171816a642cf2107b69f459ff8b534241a7636c5e34d5621c3285981f97c7b3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "What AbbVie sells, and who pays for it, is the useful way to read its low correlation to the index.",
                "category": "company",
                "datetime": 1787338129,
                "headline": "Most Of What Moves AbbVie Stock Has Nothing To Do With The Market"
              },
              {
                "id": 141278407,
                "url": "https://finnhub.io/api/news?id=d2ae63aea5848dbdb0dc5c06d23db65d6bf8f8dc67b166696e8cd91b37bc9c48",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "BMY's legacy portfolio faces generic pressure, but stronger Eliquis sales prompt a brighter 2026 revenue outlook.",
                "category": "company",
                "datetime": 1787328060,
                "headline": "Can Eliquis Cushion Bristol Myers' Legacy Portfolio Erosion?"
              },
              {
                "id": 141270900,
                "url": "https://finnhub.io/api/news?id=67fc0cda3f30767031f5016da359dec985328384ec1d4cc47c9ca40e6784c840",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "LONDON, August 21, 2026-- FORM 8.3",
                "category": "company",
                "datetime": 1787325900,
                "headline": "Form 8.3"
              },
              {
                "id": 141278607,
                "url": "https://finnhub.io/api/news?id=9c1f430fce17af8d010b3fb1eaee8275436eef26d8278df820a98e773e87580b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Nvidia initiated, Teradyne downgraded: Wall Street's top analyst calls",
                "category": "company",
                "datetime": 1787323104,
                "headline": "Nvidia initiated, Teradyne downgraded: Wall Street's top analyst calls"
              },
              {
                "id": 141279223,
                "url": "https://finnhub.io/api/news?id=4655c88fe2a76e33cf900b32f5588227e71a01a98f847568ac876f0e3b9f8ec9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
                "category": "company",
                "datetime": 1787322227,
                "headline": "3 Unpopular Stocks That Fall Short"
              },
              {
                "id": 141278039,
                "url": "https://finnhub.io/api/news?id=e68f6a3a542ae07d07afd9a4c2837484ae1d71fbd4f4419f681e7005fbb1abf7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The  exchange-traded fund, home to some large pharma companies and many smaller biotechs, has risen over 6% this week.  The main catalyst was  Moderna  and  Merck  announcement of  successful trial data for a melanoma vaccine that reduces the risk patients will experience recurrence.  “The read-through [from Merck and Moderna] to the others is probably indicative of a broader tailwind of pharma taking some strong actions to improve their long-term growth profiles,” says Cantor Fitzgerald analyst Carter Gould.",
                "category": "company",
                "datetime": 1787317680,
                "headline": "Pharma Stocks Have Rallied. 2 Stocks to Avoid—and 2 to Buy."
              },
              {
                "id": 141278874,
                "url": "https://finnhub.io/api/news?id=f1cfa27b08b3320e0d54e72acabf3bda27149596fd23f590c510bfb693a62658",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.",
                "category": "company",
                "datetime": 1787316947,
                "headline": "3 Unprofitable Stocks with Warning Signs"
              },
              {
                "id": 141271592,
                "url": "https://finnhub.io/api/news?id=4ccb9bd36bb8a00713c20c640e27a331b45cc37108e9197b705e906827562b67",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/21/Stock-And-Buyback-Write-On-Sticky-Notes-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auction. Get the offer details.",
                "category": "company",
                "datetime": 1787315770,
                "headline": "Why Is Arbutus Biopharma Stock Gaining Friday?"
              },
              {
                "id": 141279225,
                "url": "https://finnhub.io/api/news?id=dc9417d67189d08e4ddf4d001034c1198822004e2536f5ec575061c15079eb67",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "VANCOUVER, British Columbia, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Christina Lake Cannabis Corp. (the “Company” or “CLC” or “Christina Lake Cannabis”) (CSE: CLC) (OTCQB: CLCFF) (FRANKFURT: CLB) announces that it has entered into a non-binding letter of intent dated August 20, 2026 (the \"LOI\") with a private Alberta corporation (the \"Purchaser\"), to engage in due diligence and negotiations regarding the terms of a proposed transaction (the \"Proposed Transaction\") whereby the Purchaser would acquire a",
                "category": "company",
                "datetime": 1787313600,
                "headline": "Christina Lake Cannabis Announces Non-Binding Letter of Intent"
              },
              {
                "id": 141270205,
                "url": "https://finnhub.io/api/news?id=23e59dcb08810ef906b9d8c4095721cedc97b70ed29be51e108c14c6448651c6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341266246/image_1341266246.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Pfizer remains undervalued, demonstrating robust profitability and offering an attractive forward dividend yield above 6%. Read more on PFE stock here.",
                "category": "company",
                "datetime": 1787308571,
                "headline": "Pfizer: Patient Investors Will Be Rewarded"
              },
              {
                "id": 141271351,
                "url": "https://finnhub.io/api/news?id=0d2bd602fc0af6f80875672bbeb36319182caadd7697ff5dcd2b44015c9cda19",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "TORONTO, and HAIFA, Israel, Aug. 21, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that it has closed a non-brokered private placement of 1,938,326 units (“Units”) at a price of C$0.55 per Unit for aggregate gross proceeds of approximately C$1,066,078.02 (the “Offering”), subject to final acceptance of the TSX Venture Exchange",
                "category": "company",
                "datetime": 1787263260,
                "headline": "NurExone Announces Closing of C$1,066,078 Private Placement"
              },
              {
                "id": 141279227,
                "url": "https://finnhub.io/api/news?id=b18929ccd31c6bd204951919b48f6712b73ed0ed4f532ff0775b35400c7e02a9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "MISSISSAUGA, Ontario, Aug. 20, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its consolidated financial results for the three months (Q2), six months (H1), and trailing twelve months (TTM) ended June 30, 2026. Key highlights include: (CAD)Q2 2026 % Changevs. Q2 2025 H1 2026 % Changevs. H1 2025 TTMJun 30, 2026 % Changevs. TTMJun 30, 2025 Pharmaceutical Sales11,110,365 +14% 21,913,472 +7% 42,325,508 +11% Oral Health Sales8,224,402 n/a 11,209,375 n/a 11,209,375",
                "category": "company",
                "datetime": 1787263200,
                "headline": "BioSyent Releases Financial Results for Q2 and H1 2026"
              },
              {
                "id": 141279228,
                "url": "https://finnhub.io/api/news?id=eb48d8ce00fd23b5900a7747b5ea59c5a63689f1286ecaeeb657892422f5fdf7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The healthcare sector is making a comeback, with biotech stocks leading the charge. Moderna (MRNA) has been at the forefront following positive results from a melanoma vaccine trial. Yahoo Finance Markets and Data Editor Jared Blikre joins Josh Lipton on Market Domination to break down the rotation into healthcare and what it could mean for investors.",
                "category": "company",
                "datetime": 1787257320,
                "headline": "Why investors should be paying attention to biotech"
              },
              {
                "id": 141264734,
                "url": "https://finnhub.io/api/news?id=041a4c9f6cc5c0075988551d144200319109982857e66b39b37960f7eccb86a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "PEG-driven GARP picks EnerSys, Globus Medical, DoubleVerify and Match Group pair discounted valuations with strong growth potential.",
                "category": "company",
                "datetime": 1787256000,
                "headline": "4 High-Growth GARP Stocks With Discounted PEG Ratios for 2026"
              },
              {
                "id": 141279219,
                "url": "https://finnhub.io/api/news?id=8e4f93afb58f02fe18472f5ac741ac7ae74680e83c227351cf368f555f334703",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The trial met both endpoints in the readout, removing the inconclusive outcome management itself had flagged, and short sellers in the stock took a record single-session loss.",
                "category": "company",
                "datetime": 1787253674,
                "headline": "Moderna's Melanoma Result Landed On A Market Positioned The Other Way"
              },
              {
                "id": 141278041,
                "url": "https://finnhub.io/api/news?id=b6b8b6bb83ce7842471b2d3ff17fd226a74f65641d1cab1c940ba182d5fc7a99",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The products meant to offset the KEYTRUDA patent expiry were named, and two were already booking revenue, before the stock moved.",
                "category": "company",
                "datetime": 1787250436,
                "headline": "Merck Stock Ran On A Checklist Published In Advance"
              },
              {
                "id": 141278042,
                "url": "https://finnhub.io/api/news?id=a185f67366da2df6e04ff21b866c03090a3bb454dfce33b84acf2978013b48e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The medicines Pfizer has launched and acquired are arriving at close to the scale of the revenue its expiring patents will take away.",
                "category": "company",
                "datetime": 1787248494,
                "headline": "Pfizer Stock Is A Race Between New Drugs And Old Patents"
              },
              {
                "id": 141261727,
                "url": "https://finnhub.io/api/news?id=593eab7b6696fb79c76c1ab87310ffe191bf52224478eb4fdd74003a3801cac6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Two-Vials-Of-The-Moderna-Vaccine-With-A-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Healthcare stocks saw mixed after-hours moves, with Moderna and Merck cooling after explosive gains on positive cancer trial results.",
                "category": "company",
                "datetime": 1787182165,
                "headline": "Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight"
              },
              {
                "id": 141254987,
                "url": "https://finnhub.io/api/news?id=06bc9619bf53a11a041c1a94ae5eb97fa03663fcef161e2b5f6c6836998b06d4",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.",
                "category": "company",
                "datetime": 1787162702,
                "headline": "What's going on in today's session: S&P500 most active stocks"
              },
              {
                "id": 141255461,
                "url": "https://finnhub.io/api/news?id=8a923a2aeedb4a03f6cfb97eb0cbbceddf7628f540dbe08c20e1ddf7577c5e35",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Shanghai--China--Nov--6--2022-Pfizer-Sig.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Merck's deeper push into personalized cancer vaccines raises the competitive bar for Pfizer, BioNTech in biotech's fastest-growing race.",
                "category": "company",
                "datetime": 1787149875,
                "headline": "Merck Just Raised the Stakes for Pfizer's Cancer Vaccine Ambitions"
              },
              {
                "id": 141255462,
                "url": "https://finnhub.io/api/news?id=2b286492921519f765948c500cb6a5dbb1095b7ae86a0c930813419698ce748e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Logo-Pfizer-Inc--Is-An-American-Multinat.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Pfizer Inc (NYSE:PFE) shares are trading higher Wednesday, moving in sympathy with mRNA cancer vaccine-related companies after Merck & Co Inc (NYSE:MRK) and Moderna Inc (NASDAQ:MRNA) announced that their combination therapy of intismeran autogene and Keytruda showed positive recurrence-free survival results in melanoma patients.",
                "category": "company",
                "datetime": 1787147774,
                "headline": "Pfizer Stock Rises Wednesday: What's Going On?"
              },
              {
                "id": 139941575,
                "url": "https://finnhub.io/api/news?id=987aa0ba24b74bed168e38bd5d8117088eb5cd2a1d0eaeb67de7b61cd2be93c4",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "",
                "category": "company",
                "datetime": 1787141736,
                "headline": "ImmunityBio Expands Commercial Access For ANKTIVA Bladder And Lung Cancer Treatment To Saudi Arabia"
              },
              {
                "id": 141253313,
                "url": "https://finnhub.io/api/news?id=2e1130e90380ab9807504bf240b0038a51a19924cdacc932dd13f4834b335bfb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1688769969/image_1688769969.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Rumors of an AstraZeneca PLC-Bristol-Myers Squibb Company merger are cooling. Click here for risks and drug portfolio insights on BMY and AZN stock.",
                "category": "company",
                "datetime": 1787131330,
                "headline": "AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?"
              },
              {
                "id": 141245599,
                "url": "https://finnhub.io/api/news?id=af9e9891c36a35905a94feb76585bb6875f18fcb3e7f02310634986236b6873c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2279213066/image_2279213066.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Build a durable 9% yield retirement income portfolio—dividends to cover expenses without forced sales. Read the full analysis here.",
                "category": "company",
                "datetime": 1787044500,
                "headline": "The 9% Portfolio That Retires Your Paycheck"
              },
              {
                "id": 141245137,
                "url": "https://finnhub.io/api/news?id=cb69904af5d30282ff1a8d170381797b4c39dcaeece33b4ccb352f2b52a2ecac",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2178115949/image_2178115949.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Pfizer reported second quarter results, and the company did beat analysts’ estimates for revenue as well as earnings per share. Read why PFE stock is a buy.",
                "category": "company",
                "datetime": 1787036663,
                "headline": "Pfizer: Still Cheap Valuation Meets A Looming Patent Cliff"
              },
              {
                "id": 141239369,
                "url": "https://finnhub.io/api/news?id=a245f182d8a1d967af429370e7a6ae69b57fe2b551fd2b28df79504cb335ba28",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Looking for the most active stocks in the S&P500 index on Monday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market.",
                "category": "company",
                "datetime": 1786989900,
                "headline": "These S&P500 stocks are the most active in today's session"
              },
              {
                "id": 141239729,
                "url": "https://finnhub.io/api/news?id=ccd2ea8851c0b4b01e6bcf4847b75690ef0993697f38657d9476c66c127a9022",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1786973716,
                "headline": "4 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 141230802,
                "url": "https://finnhub.io/api/news?id=f27678b5a5ecd46e15edc0e77302ec2996e442f4cec8d95c252a55f426f58c84",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/472209441/image_472209441.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Preview key market catalysts: Walmart, Target & Home Depot earnings, Fed minutes, PMI data, and S&P 500 changes.",
                "category": "company",
                "datetime": 1786861929,
                "headline": "Wall Street Week Ahead"
              },
              {
                "id": 141218823,
                "url": "https://finnhub.io/api/news?id=7bfe534a70390038e10d17cbb2c82f1b487ed3146bc75f42546c6b75ccffa9f2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/14/Vaccine.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Valneva (VALN) stock surges after EMA validates MAA for Lyme disease vaccine candidate developed with Pfizer (PFE). Phase 3 trial showed efficacy and no safety concerns, pending regulatory approval.",
                "category": "company",
                "datetime": 1786711574,
                "headline": "European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application"
              },
              {
                "id": 141220994,
                "url": "https://finnhub.io/api/news?id=abeeb106c459bfd415bf320c72c4c775eac1ff0d43af0e5b952acb0865b61db0",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "A August filing shows that Representative Carol Miller reported a sale in Pfizer (NYSE:PFE), valued between $60,004 and $200,000. The transaction date is listed as March 10, 2025, with the report published on August 13,",
                "category": "company",
                "datetime": 1786705331,
                "headline": "Recent Filing Shows That Rep. Carol Miller Sold Over $60K Worth of Pfizer Stock"
              },
              {
                "id": 141215069,
                "url": "https://finnhub.io/api/news?id=f7114945d59b91775591be93c045ca3633988fe3d1b6f5898f2a030ec0259ef8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "NEW YORK & LYON, France, August 14, 2026--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies’ 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application.",
                "category": "company",
                "datetime": 1786683600,
                "headline": "Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency"
              },
              {
                "id": 141216490,
                "url": "https://finnhub.io/api/news?id=c2c51ff900748cc919958f244e5ad7f758483c9476ba1a33f0011d2bf799c198",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/14/The-Real-Villains-No-Longer-Hide.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Eton Pharmaceuticals Inc (NASDAQ: ETON) rose in pre-market trading after reporting strong Q2 results and issuing FY26 revenue guidance above estimates.",
                "category": "company",
                "datetime": 1786682245,
                "headline": "Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket"
              },
              {
                "id": 140013274,
                "url": "https://finnhub.io/api/news?id=c5cbe2f06e69173640b9cf6c14e9d85950201555291b56af9a7688f8df4a16fb",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "",
                "category": "company",
                "datetime": 1786669587,
                "headline": "Valneva shares are trading lower after the company announced with Pfizer topline results from the Phase 3 VALOR \"Vaccine Against Lyme for Outdoor Recreationists\" clinical trial. The vaccine candidate PF-07307405 demonstrated efficacy of more than 70% in preventing Lyme disease in individuals aged five years and above."
              },
              {
                "id": 141209482,
                "url": "https://finnhub.io/api/news?id=ae5bdda631a70f2a87b44e4b66f3b5b884b69988e3004f5e5d804963bbdbc05f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Valneva (NASDAQ:VALN) reported lower first-half revenue and wider losses for 2026, while maintaining its full-year sales outlook and emphasizing its cash position, restructuring measures and expectations for regulatory progress on its Lyme disease vaccine candidate with Pfizer. CEO Thomas Lingelbac",
                "category": "company",
                "datetime": 1786647861,
                "headline": "Valneva Q2 Earnings Call Highlights"
              },
              {
                "id": 141209483,
                "url": "https://finnhub.io/api/news?id=3c50b192e42afc7959b9d6c5187a3c0d70a3787a21eaf75845d638618c8d799a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Nearly nine in ten EU4+UK hematologists now require longer-term efficacy data before referring patients with hemophilia A for gene therapy, while Spherix patient research reveals continued interest in the modality.Exton, PA, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The hemophilia gene therapy market is contracting commercially, but physician and patient interest in the modality has not disappeared. Recent commercial developments, including the discontinuation of BEQVEZ® (Pfizer), withdrawal of ROCTAVIA",
                "category": "company",
                "datetime": 1786647540,
                "headline": "Gene Therapy Remains Top-of-Mind in Hemophilia Despite Recent Market Contraction, as Physicians and Patients Raise the Bar for Success"
              },
              {
                "id": 141207923,
                "url": "https://finnhub.io/api/news?id=88a90702b18759d550549111dea289f1d88362148d397438d1ad60ef07c20c75",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.",
                "category": "company",
                "datetime": 1786637411,
                "headline": "The Sharpest Exchanges From ABBV's Earnings Call"
              },
              {
                "id": 141206622,
                "url": "https://finnhub.io/api/news?id=834e68a730234edefb17d792b46fff00c1c6f2944ccc0a22b3f604a8b4eb6da1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "In early August 2026, Pfizer Inc. reported second-quarter results showing revenue of US$15,034 million and a net loss of US$248 million, alongside US$4.30 billion in non-cash intangible asset impairments and a modest increase in full-year 2026 revenue guidance to US$60.50–US$62.50 billion. A key offsetting highlight was the positive Phase 3 data for Pfizer’s autoimmune drug LITFULO in nonsegmental vitiligo, underlining the growing importance of its non-COVID portfolio and broader immunology...",
                "category": "company",
                "datetime": 1786633961,
                "headline": "How Pfizer’s Higher 2026 Guidance And LITFULO Trial Results At Pfizer (PFE) Have Changed Its Investment Story"
              },
              {
                "id": 141206444,
                "url": "https://finnhub.io/api/news?id=52bfa7e35dde7a9ac989f6330dfa4e876871b264aac6960fbbbe3c1c17a70378",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The Advertising Research Foundation (ARF) today announced the finalists for the 2026 ARF David Ogilvy Awards, honoring excellence in research-driven advertising and marketing.",
                "category": "company",
                "datetime": 1786633320,
                "headline": "The Advertising Research Foundation Announces 2026 ARF David Ogilvy Awards Finalists"
              },
              {
                "id": 141205587,
                "url": "https://finnhub.io/api/news?id=ee149afdd7845ac06c38622b9bf67674688ee202ce2eb54f27125b46d8f5e47b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Albert Bourla adds 38,000 shares.",
                "category": "company",
                "datetime": 1786623646,
                "headline": "Pfizer CEO Buys $1 Million of Stock"
              },
              {
                "id": 141205521,
                "url": "https://finnhub.io/api/news?id=6832e14b21f0874656f33283932f5bb0210df135957773398747c23a6f14a2bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Well-known pharmaceutical companies such as  Merck  and  Pfizer  typically manage this complex process in house.  Medpace Holdings  which targets oncology, metabolic, cardiology, central nervous system, and anti-infective therapies, raised its 2026 revenue guidance on July’s second-quarter conference call to a midpoint of $2.85 billion, corresponding to a year-over-year increase of 13%.  Three months later, Medpace is in the pink: On the heels of second-quarter earnings, the stock is up 14%.",
                "category": "company",
                "datetime": 1786622460,
                "headline": "This Healthcare Services Stock Has 37% Upside"
              },
              {
                "id": 141201259,
                "url": "https://finnhub.io/api/news?id=f4d58bf3a8eb3297142ff265493be229f5d1f5432c1e0a32c3ed66281ef8c7fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "SPRO strengthens its balance sheet and extends cash runway into 2029 while advancing its new SP001 immunology pipeline following the landmark approval of the first oral carbapenem antibiotic.",
                "category": "company",
                "datetime": 1786597284,
                "headline": "Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ..."
              },
              {
                "id": 141201260,
                "url": "https://finnhub.io/api/news?id=5323415d0a54de4967d0a77becd945f6a79d31103a9dbf185d6c475d5b5955d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Total product sales of €64.0 million In-line with expectations; full-year guidance of €135 -150 million reaffirmed Solid cash position of €121.5 million as of end June 2026 Reflects disciplined cash management and proceeds from the recent reserved offering1 Restructuring program implemented with positive P&L and cash flow impacts expected in the second half of the year and beyond Regulatory decisions for Lyme disease vaccine candidate expected in the next twelve months2 Pfizer remains optimistic",
                "category": "company",
                "datetime": 1786597200,
                "headline": "Valneva Reports Half Year 2026 Financial Results and  Provides Corporate Updates"
              },
              {
                "id": 141201261,
                "url": "https://finnhub.io/api/news?id=cf8edf845ef0b119e311ea0f406e1111fbe27c66b2cf07b31caba82f0c18d6f6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer’s second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company’s performance was shaped by strong execution in its non-COVID portfolio, with management highlighting robust revenue contributions from acquired brands and recent launches. CEO Albert Bourla attributed operational progress to “continued strategic progress” and emphasized the value generated by recent acquisitions such as Seagen and Biohaven. Management",
                "category": "company",
                "datetime": 1786588140,
                "headline": "5 Insightful Analyst Questions From Pfizer’s Q2 Earnings Call"
              },
              {
                "id": 141206330,
                "url": "https://finnhub.io/api/news?id=b48a49126c69ae7754badde85bb6d7fde33ff1c2762086ba9e2bc250215c8ab7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/13/3d-Rendering-Of-A-Red-Medical-Capsule-An.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "China’s science surge is reshaping global drug development as Washington moves to counter Beijing’s growing influence in medicine.",
                "category": "company",
                "datetime": 1786574462,
                "headline": "Big Pharma's Future Growth Rests on Chinese Science? Expert Says: 'We Can't Ban Our Way Out of This'"
              },
              {
                "id": 141200401,
                "url": "https://finnhub.io/api/news?id=9f8326d5bf4c5cc8712afd3a3a64b28f795699272f51d641a706f97680ee3451",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The drugmaker's operating numbers are near the top of its class, but its stock performance is lagging the pack. Is the market seeing a risk that the fundamentals are missing.",
                "category": "company",
                "datetime": 1786567769,
                "headline": "How ABBV Stock Moved Away From Its Peer Group"
              },
              {
                "id": 141200512,
                "url": "https://finnhub.io/api/news?id=00bc77a193caee8506d9c2f7e49efdf6fa5f4b117ad9f052361cece75a324ba4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Management raised its full-year forecast, but the market seems to be asking for more than a higher target.",
                "category": "company",
                "datetime": 1786562251,
                "headline": "Amgen Stock And The Price Of A Promise"
              },
              {
                "id": 141200784,
                "url": "https://finnhub.io/api/news?id=a0f94fad322cade1b1dfddb9e669db562bae82620561c6509b5ce01c01288c55",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Bristol Myers growth portfolio now accounts for 56% of revenues, led by key drugs, including Opdivo Qvantig, Reblozyl and Breyanzi, helping offset generic erosion.",
                "category": "company",
                "datetime": 1786559760,
                "headline": "Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?"
              },
              {
                "id": 141194478,
                "url": "https://finnhub.io/api/news?id=89440173c0d17d0687c2c2d7bfb0f562b83c3f2aa5af7ba97e4b1195b6f44021",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Let's have a look at what is happening on the US markets on Wednesday. Below you can find the most active S&P500 stocks in today's session.",
                "category": "company",
                "datetime": 1786557901,
                "headline": "Which S&P500 stocks are the most active on Wednesday?"
              },
              {
                "id": 141200407,
                "url": "https://finnhub.io/api/news?id=3d4976f509abb60cfa4a755d78912638903405f4f6f5178c1b363bd7a7279a15",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "PFE's non-COVID products are gaining momentum, with launches, acquisitions and a pipeline aimed at driving growth from 2029 onward.",
                "category": "company",
                "datetime": 1786546980,
                "headline": "Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?"
              },
              {
                "id": 141194603,
                "url": "https://finnhub.io/api/news?id=e239e42b732188ca7b851e111a440215ab9cdc197a501d0d5abc0d3274a14b74",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will",
                "category": "company",
                "datetime": 1786541715,
                "headline": "10 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 141200518,
                "url": "https://finnhub.io/api/news?id=78cd813b9ec063ef31be0d6d0b44ffefcc96b5fa0be5dba40387d36f5497337d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "RAS mutations fuel nearly a third of all cancers, and one biotech has quietly built the deepest late-stage pipeline targeting them. Now the biggest names in pharma are circling, and the math on who can actually write the check gets complicated fast.",
                "category": "company",
                "datetime": 1786539024,
                "headline": "Why Revolution Medicines May Be Big Pharma’s Next Takeover Target"
              },
              {
                "id": 141200996,
                "url": "https://finnhub.io/api/news?id=85f3c4dcca9245316fb9cc97b5e1442f57eedf98cdeea73f35e9dcccc398519c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The S&P 500's dividend yield just hit a record low, leaving income investors scrambling for alternatives. Five long-established index members still pay 6% or more, and all carry Buy ratings from top Wall Street analysts.",
                "category": "company",
                "datetime": 1786536915,
                "headline": "The S&P 500 Yield Is the Lowest in History: 5 Members of the Legacy Index Yield 6% or More"
              },
              {
                "id": 141193636,
                "url": "https://finnhub.io/api/news?id=7bfc4b9332d97a09de7dfbe3cb43cc3e1d4b127d00f25ae64f7b45081dc0433c",
                "image": "",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "",
                "category": "company",
                "datetime": 1786536901,
                "headline": "I Underestimated Eli Lilly: Retatrutide Changes The Risk/Reward (Rating Upgrade)"
              },
              {
                "id": 141201268,
                "url": "https://finnhub.io/api/news?id=fe0064a7c655ccaff3e90adfadaeb34185900cc00cbc37e1bc89b554127c7141",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first payment of approximately $178M from Moderna settlement in July and expects to return up to approximately $230M in capital to Arbutus shareholders Filed three international patent enforcement lawsuits against Pfizer and BioNTech related to lipid nanoparticle (LNP) technology Achieved alignment with the U.S. Food and Drug Administration (FDA) on a proposed imdusir",
                "category": "company",
                "datetime": 1786534200,
                "headline": "Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update"
              },
              {
                "id": 141201269,
                "url": "https://finnhub.io/api/news?id=e969e5e0fa3036cab2d14d4bf28d02c62ae9255d4adf780f53b09798d7449cbf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (NYSE:PFE) agreed to a US$44 million class action settlement related to its smoking cessation drug Chantix, addressing claims tied to product safety disclosures. The company reported positive topline Phase 3 results for LITFULO in adults and adolescents with nonsegmental vitiligo, highlighting progress in its immunology pipeline. Both developments arrive as investors track Pfizer's legal exposures alongside late stage trial data that could inform future portfolio and revenue...",
                "category": "company",
                "datetime": 1786513179,
                "headline": "Pfizer (PFE) Agreed To A $44 Million Chantix Settlement"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 1,
            "positive_hits": 1,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0,
            "source_article_count": 216,
            "discarded_article_count": 207
          },
          "sentimentPoints": 2
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 17,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 2.7,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": true,
            "vcp_score": 2.7,
            "vcp_reason": "波幅收縮(16.8%→6.5%)；跌縮量(近10日6日)；站上MA50；升放量(近10日3日)；Ready=Y；Confirm=Y",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 37327596.666666664,
              "down_days": 6,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 32626580,
              "avg_vol_20": 33287960,
              "avg_vol_30": 37327596.666666664,
              "range_pct_10": 0.06529581529581538,
              "range_pct_20": 0.10101010101010104,
              "range_pct_30": 0.16810966810966813,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 3,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.8740605587697896,
              "dist_to_20d_high": 0.051009928106812805,
              "down_shrink_days": 6,
              "breakout_level_20d": 29.21,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.38841201716738244
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 1.961038961038961,
              "turnoverUsdM": 707.68478088,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1.2
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.PFE",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 26.6328,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2.5,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.3,
            "stop_loss_percent": 3.9,
            "take_profit_price": 29.106,
            "target_multiplier": 1.6,
            "technical_strength": 1.45,
            "take_profit_percent": 5
          },
          "positionPoints": 1.8,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.274834437086093,
          "stopLossPercent": 3.922077922077922,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.PFE",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 0.5436,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 8,
      "atr_pct": 1.96
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -48.41
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.1368
    },
    "kdj": {
      "d": 40.1,
      "j": -3.89,
      "k": 25.43,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 42.14
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 6,
      "trend": "有流入",
      "value": -16774746,
      "recentSlope": 1301735.4,
      "previousSlope": 4618800
    },
    "rsi": 45.41,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 29.0128,
      "position": "SAR喺價上",
      "distancePct": 4.66,
      "previousTrend": "下降"
    },
    "ma50": 26.2684,
    "macd": {
      "macd": 0.4519593933256303,
      "trend": "中性偏多",
      "signal": 0.6324237225007052,
      "histogram": -0.18046432917507493
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 28.0223,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.78,
      "score": 2,
      "avgVolume": 32796658,
      "currentVolume": 25529754
    },
    "derived": {
      "ma20": 28.003,
      "ma50": 26.2684,
      "prevClose": 27.65,
      "avgVolume10": 32062115,
      "avgVolume20": 32796658,
      "changePercent": 0.25,
      "avgVolumeForScore": 32796658
    },
    "ma_cross": {
      "ma20": 28.003,
      "ma50": 26.2684,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 27.957,
      "prevMa50": 26.1916,
      "spreadPct": 6.6,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 26.8598,
      "upper": 29.1462,
      "position": "中間"
    },
    "rsi_short": 4.86,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.78
    }
  }
}

{
  "close": 27.72,
  "volume": 25529754,
  "changePercent": 0.25
}